Characterisation of oestrogenic properties of Isoflavones derived from Millettia griffoniana Baill.: - Molecular mode of action and tissue selectivity by Ketcha Wanda, Germain Jean Magloire
 
Characterisation of oestrogenic properties of 
Isoflavones derived from Millettia griffoniana Baill.: 
-Molecular mode of action and tissue selectivity 
 
 
 
 
 
Dissertation 
 
 
zur Erlangung des akademischen Grades  
Doktor rerum naturalium (Dr. rer. nat.) 
Der Fakultät Mathematik und Naturwissenschaften 
der Technischen Universität Dresden 
 
 
vorgelegt von 
M.Sc. Germain Jean Magloire Ketcha Wanda  
aus Bantoum I, Kamerun 
 
 
eingereicht am 12.05.2006 
  
 
Gutachter:     Prof. Dr. habil. Günter Vollmer        
Prof. Dr. habil. Herwig O. Gutzeit 
Priv. Dz. Dr. habil. Patrick Diel 
 
 
Datum der Verteidigung:  20.07.2006 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gedruckt mit der Unterstützung des Deutschen Akademischen Austauschdienstes 
(DAAD)
  Dedication 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I dedicate this work to: 
   - My wife Bergeline Tchangoue Epouse Ketcha 
   - Borell Njonkoe Ketcha 
   - Loic Vianney Towa Ketcha 
   - Astrid Owona Ketcha 
 
 
 
 
 
  Table of contents 
 
 i
Table of contents 
Table of contents.................................................................................................................i 
List of tables .......................................................................................................................v 
List of figures .....................................................................................................................v 
List of abbreviations...................................................................................................... viii 
Summary ............................................................................................................................x 
 
1 Introduction ....................................................................................................................1 
1.1 current state of knowledge .................................................................................................... 1 
1.2 Aim of the study.................................................................................................................... 2 
1.3 Approach to the study ........................................................................................................... 3 
1.4 Thesis outline ........................................................................................................................ 3 
 
2 Background and literature review ................................................................................5 
2.1 Oestrogens............................................................................................................................. 5 
2.1.1 Synthesis of oestogens..................................................................................................................5 
2.1.2 Endogenous sources of oestrogens ...............................................................................................6 
2.1.3 Transport and metabolism of oestrogens ......................................................................................7 
2.2 Physiological actions of oestrogens ...................................................................................... 7 
2.2.1 Actions on the female reproductive system..................................................................................7 
2.2.2 Oestrogenic effects on the cardiovascular system ........................................................................8 
2.2.3 Effects on bone .............................................................................................................................8 
2.3 Oestrogen receptors............................................................................................................... 9 
2.3.1 Discovery of oestrogen receptors .................................................................................................9 
2.3.2 Structural and functional domains of oestrogen receptors..........................................................10 
2.3.3 Distribution of oestrogen receptors ............................................................................................11 
2.3.4 Regulation of oestrogen receptors ..............................................................................................12 
2.4 Mechanism of Action of oestrogens.................................................................................... 13 
2.4.1 Classical gene regulatory pathway (for oestrogen action) ..........................................................13 
2.4.1.1 Oestrogen Response Element .............................................................................................13 
2.4.1.2 Coactivators and corepressors of oestrogen receptors ........................................................14 
2.4.2 ERE-independent pathways........................................................................................................15 
2.4.2.1 AP-1 pathway .....................................................................................................................15 
2.4.2.2 SP1 pathway .......................................................................................................................16 
2.4.2.3 NF-κB pathway...................................................................................................................16 
2.4.3 Non genomic pathway................................................................................................................17 
2.4.3.1 Phosphatidylinositol 3-kinase (PI3K)-Akt Pathway ...........................................................17 
2.4.3.2 Mitogen activated protein kinase (MAPK) pathway...........................................................18 
2.4.4 Oestrogen-independent pathways...............................................................................................18 
2.5 Oestrogen antagonists or antiestrogens ............................................................................... 19 
2.5.1 Selective oestrogen receptor modulator (SERM) .......................................................................19 
2.5.2 Pure oestrogen antagonists/ antioestrogens ................................................................................20 
2.6 Oestrogen disruptors/environmental oestrogens ................................................................. 21 
2.6.1 “Xeno-oestrogens” .....................................................................................................................21 
2.6.2 Synthetic oestrogens...................................................................................................................21 
2.6.3 Phytoestrogens............................................................................................................................21 
2.6.3.1 Isoflavones..........................................................................................................................22 
  Table of contents 
 
 ii
2.6.3.2 Flavonoids...........................................................................................................................23 
2.6.3.3 Lignans ...............................................................................................................................23 
2.6.3.4 Coumestans.........................................................................................................................23 
2.7 Millettia griffoniana ............................................................................................................ 24 
2.7.1 Botanical studies/distribution .....................................................................................................24 
2.7.2 Description of plants of the genus Millettia................................................................................24 
2.7.3 Phytochemistry/active constituents ............................................................................................24 
2.7.4 Traditional use and application of Millettia griffoniana .............................................................25 
2.8 Oestrogen-responsive genes used as marker genes............................................................. 25 
2.8.1 Cytochrom C oxidase (1A).........................................................................................................25 
2.8.2 Proliferating cell nuclear antigen (PCNA)..................................................................................26 
2.8.3 Ki-67...........................................................................................................................................26 
2.8.4 Cyclin D1 (CD1) ........................................................................................................................26 
2.8.5 Complement component 3 (C3)..................................................................................................26 
2.8.6 Calcium binding protein 9 kilo Dalton (CaBP 9kD) ..................................................................27 
2.8.7 Progesterone receptor (PR).........................................................................................................27 
2.8.8 Vascular endothelial growth factor (VEGF) and VEGF-receptor 2 (VEGFR-2) .......................27 
2.8.9 Clusterin (CLU)..........................................................................................................................28 
2.8.10 Cyclooxygenase 2 (COX 2)......................................................................................................28 
2.8.11 Insulin like growth factor 1 (IGF-1) .........................................................................................29 
2.8.12 Insulin like growth factor binding protein 1 (IGFBP-1) ...........................................................29 
2.8.13 Carbonic anhydrase 2 (CA 2) ...................................................................................................29 
2.8.14 Major acut phase protein (MAP) ..............................................................................................29 
2.8.15 Apolipoprotein A I (ApoA-I) ...................................................................................................30 
2.8.16 Hepatic nuclear factor 3 γ (HNF-3γ) ........................................................................................30 
2.8.17 Angiotensin converting enzyme (ACE)....................................................................................30 
2.8.18 Nitric oxide synthase 3 (NOS 3)...............................................................................................30 
 
3 Materials and Methods ................................................................................................32 
3.1 Materials.............................................................................................................................. 32 
3.1.1 Solutions and buffers ..................................................................................................................32 
3.1.2 Culture media for yeast...............................................................................................................35 
3.1.3 Test organisms............................................................................................................................36 
3.1.3.1 Yeast strain .........................................................................................................................36 
3.1.3.2 Cell lines (Human cells) .....................................................................................................36 
3.1.3.3 Animals...............................................................................................................................37 
          3.1.4 Substances....................................................................................................................................37 
3.1.5 Test chemicals –  plant extracts ..................................................................................................37 
3.2 Methods............................................................................................................................... 40 
3.2.1 Preparation of DCC-FCS solution ..............................................................................................40 
3.2.2 Cell culture of MCF-7, MVLN and Ishikawa cells ....................................................................40 
3.2.3 Yeast recombinant assay ............................................................................................................40 
3.2.3.1 Preparation of Growth medium ..........................................................................................40 
3.2.3.2 Assay procedure- Incubation with tests substances ............................................................40 
3.2.4 Luciferase reporter gene assay....................................................................................................41 
3.2.4.1 Assay procedure..................................................................................................................41 
3.2.4.2 Luciferase activity...............................................................................................................41 
3.2.5 Alkaline phosphatase assay with Ishikawa cells.........................................................................42 
3.2.6 Gene expression..........................................................................................................................42 
3.2.6.1 Primer design ......................................................................................................................42 
3.2.6.2 Primer optimization and efficiency measurement...............................................................43 
3.2.6.3 Treatment of MCF-7 cells for gene expression analysis.....................................................43 
3.2.7 Uterotrophic bioassay.................................................................................................................43 
3.2.8 Total mRNA extraction from cells and tissues. ..........................................................................44 
3.2.9 DNAse digestion of genomic DNA............................................................................................44 
3.2.10 Complementary DNA (cDNA) synthesis .................................................................................45 
3.2.10.1 Method of Sambrook and Manniatis.................................................................................45 
3.2.10.2 Invitrogen Protocol using Superscript II ...........................................................................45 
  Table of contents 
 
 iii
3.2.11 Real-time PCR..........................................................................................................................46 
3.2.12 Analysis of real-time PCR results.............................................................................................47 
3.2.13 Effects of Griffonianone C and 17β-oestradiol on Protein kinase B (Akt)  
expression in MCF-7 cells...................................................................................................................48 
3.2.13.1 Assay procedure................................................................................................................48 
3.2.13.2 Cell lysate and preparation of protein samples .................................................................48 
3.2.14 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) .......................48 
3.2.14.1 Electrophoresis .................................................................................................................48 
3.2.14.2 Immunoblotting ................................................................................................................49 
3.2.14.3 Detection of protein kinase B (Akt)..................................................................................49 
3.2.14.4 Membrane stripping and re-probing .................................................................................49 
3.2.15 Statistical analysis ....................................................................................................................50 
 
4 Results............................................................................................................................51 
4.1 Response of the yeast screening to isoflavones from Millettia griffoniana ........................ 51 
4.2 Effects of isoflavones from Millettia griffoniana on the luciferase expression .................. 52 
4.3 Oestrogenic effects on the alkaline phosphatase activity in Ishikawa cells ........................ 54 
4.4 Antagonisation by fulvestrant ............................................................................................. 55 
4.5 Effects of Griff C on Ki-67, CD1 and PCNA mRNA expression in MCF-7  
breast cancer cells. .................................................................................................................... 56 
4.5.1 Effect of Griff C on the mRNA expression of Ki-67, CD1 and PCNA in MCF-7 cells.............56 
4.6 Uterotrophic assay............................................................................................................... 57 
4.6.1 Uterus wet weight.......................................................................................................................57 
4.6.2 Gene expression in uterus...........................................................................................................58 
4.6.2.1 Oestrogen Receptors α and β mRNA expression................................................................58 
4.6.2.2 Complement C3 and Calcium Binding Protein 9kD mRNA expression ............................59 
4.6.2.3 Vascular Endothelial Growth Factor and Progesterone Receptor mRNA expression ........60 
4.6.2.4 Clusterin and Cyclooxygenase 2 mRNA expression ..........................................................61 
4.6.2.5 Insulin-Like Growth Factor mRNA expression..................................................................62 
4.7 Oestrogenic responses in other target organs. ..................................................................... 62 
4.7.1 Gene expression in the liver of ovariectomised rats......................................................... 62 
4.7.1.1 Clusterin and Insulin-Like Growth Factor Binding Protein I mRNA expression....................63 
4.7.1.2 Major Acute Phase Protein and Carbonic Anhydrase 2 mRNA expression ............................63 
4.7.1.3 Apolipoprotein A-I and Hepatic Nuclear Factor 3γ mRNA expression ..................................64 
4.7.2 Gene expression in vena cava of ovariectomised rats ...................................................... 65 
4.7.2.1 Oestrogen Receptor α and Progesterone Receptor mRNA expression ....................................65 
4.7.2.2 Vascular Endothelial Growth Factor (VEGF) and VEGF-Receptor-2 mRNA expression......65 
4.7.2.3 Angiotensin Converting Enzyme and Nitric Oxide Synthase 3 mRNA expression ................66 
4.7.2.4 Proliferating Cell Nuclear Antigen and Ki-67 mRNA expression...........................................67 
4.7.2.5 Clusterin and Cyclooxygenase 2 mRNA expression ...............................................................67 
4.8 Western blot analysis of the expression of Akt and phosphorylated  
Akt proteins in MCF-7 cells...................................................................................................... 68 
4.8.1 Effects of E2, and Griff C on the Akt activation ........................................................................68 
4.8.2 Akt activation is affected by the PI3K inhibitor LY294002 and not by fulvestrant ...................69 
 
5 Discussion ......................................................................................................................70 
5.1 Oestrogenic activity of compounds from Millettia griffoniana in a yeast screening assay. 70 
5.2 Oestrogenic effects of Millettia griffoniana and 17β-oestradiol in MVLN and Ishikawa cells
................................................................................................................................................... 70 
5.3 Antagonism of oestrogenic effects of Millettia griffoniana and 17β-oestradiol by fulvestrant 
in MVLN and Ishikawa cells .................................................................................................... 71 
  Table of contents 
 
 iv
5.4 Regulation of PCNA, KI-67 and CD1 mRNA expression in MCF-7 cells......................... 72 
5.5. Effects of griffonianone C in ovariectomised rats.............................................................. 73 
5.5.1. Uterotrophic effects and regulation of oestrogen-regulated genes in the uterus........................73 
5.5.2. Oestrogen-mediated gene expression in liver ............................................................................77 
5.5.3. Oestrogen-induced gene expression in vena cava .....................................................................78 
5.6. In vitro regulation of Akt activation in MCF-7 breast cancer cells.................................... 80 
 
6 Conclusion and future outlook ....................................................................................82 
 
References.........................................................................................................................84 
 
Appendix ........................................................................................................................118 
A. Chemicals .....................................................................................................................118 
B. Supplies ........................................................................................................................126 
C. Equipments ...................................................................................................................127 
D. Kits used .......................................................................................................................129 
E. Antibodies .....................................................................................................................129 
F. Software used ................................................................................................................129 
 
Curriculum vitae............................................................................................................130 
 
Acknowledgements ........................................................................................................132 
 
List of publications and presentations .........................................................................134 
 
Pledge..............................................................................................................................135 
  List of tables and figures 
 
 v
List of tables 
Table 1: Chemical composition of buffer used for cell washing (PBS). The components 
were dissolved in 5 l dd water and adjusted to pH 7.4. ..................................................................33 
Table 2: preparation of PAGE gels...................................................................................................34 
Table 3: The basic chemical composition of the medium for yeast culture......................................36 
Table 4: outline of the treatment.......................................................................................................44 
Table 5: Reaction setup for one real-time PCR. ...............................................................................46 
Table 6: Cycling conditions for real-time-PCR ................................................................................47 
Table 7: Uterine wet weight of Wistar ovariectomised rats after daily s.c. injection of 
carrier castor oil (OVX), oestradiol (E2) and Griffonianone C. Data represent means 
± SD, * indicates a significant difference as compared to the vehicle-treated animals. 
***p< 0.001....................................................................................................................................58 
 
List of figures  
Fig. 1. Molecular structures of Oestradiol (1), estrone (2) and estriol (3)...........................................6 
Fig. 2. Synthesis of oestradiol and estrone (adapted from: Production and actions of 
oestrogens, (Gruber, 2002) ...............................................................................................................6 
Fig. 3. Effects of oestrogens in different organ systems (from Gruber et al., 2002) ...........................9 
Fig. 4. Schematic diagram of two human receptors, ERα and ERβ (adapted from 
Wenlin Shao and Brown, 2003). ....................................................................................................11 
Fig. 5. Schematic representation of the major human tissues expressing ERα and ERβ 
in female (left) and male (right) (from Enmark and Gustafsson 1998). .........................................12 
Fig. 6. Diagram of the role of ER coregulators in gene transactivation (from Tremblay 
and Giguère, 2002) .........................................................................................................................15 
Fig. 7. Selected non-nuclear and nuclear activities of ERα (Ho and Liao, 2002) .............................18 
Fig. 8. Chemical structure of fulvestrant. ..........................................................................................20 
Fig. 9. General structure of isoflavones ............................................................................................23 
Fig. 10. Chemical structures of compounds extracted from Millettia griffoniana and 
used in the current investigations ...................................................................................................39 
Fig. 11 (a, b). Oestrogenic effects of test substances on the Lac-Z induction in human 
oestrogen receptor (hER) recombinant yeast. Data represent the mean ± SD of four 
independent experiments. ...............................................................................................................52 
Fig. 12 (a, b). Effects of Isoflavones from Millettia griffoniana on luciferase induction. 
Results are expressed as percentage of the positive control oestradiol at the 
concentration 10-8 M set at 100%. Data represent the mean ± SD of three 
independent experiments. *p< 0.05, **p< 0.005, ***p< 0.001 significantly different 
from the control group....................................................................................................................53 
Fig. 13 (a, b). Dose-response of phytochemicals on the alkaline phosphatase activity in 
Ishikawa cells. Data represent the mean ± SD of three independent experiments.  
**p< 0.005, ***p< 0.001 significantly different from the control group.......................................54 
Fig. 14. Relative induction of luciferase by simultaneous treatment with the pure 
antagonist fulvestrant (5x10-7 M), oestradiol (10-8 M) or test compounds at the 
concentration 10-6 M. §p< 0.05 (student’s t-test) ..........................................................................55 
Fig. 15. Relative induction of luciferase by simultaneous treatment with fulvestrant 
(5x10-7 M), oestradiol (10-7 M) or test compounds at the concentration of 10-6 M. 
§p< 0.05 (student’s t-test)...............................................................................................................56 
Fig. 16. Dose-response effects of Griff C on the mRNA expression of proliferation 
markers Ki-67, PCNA and CD1 in MCF-7 cells............................................................................57
  List of figures 
 
 vi
 
Fig. 17. Oestrogen Receptors α and β mRNA expression in uterus of Wistar 
ovariectomised rats. Data represent means ± SD. * indicates a significant difference 
as compared to the vehicle-treated animals. *p< 0.05, ** p< 0.005, ***p< 0.001. .......................58 
Fig. 18 (a, b). C3 mRNA expression in uterus of Wistar ovariectomised rats. Data 
represent means ± SD. * indicates a significant difference as compared to the vehicle-
treated animals **p< 0.005, ***p< 0.001. Note that b) is identical to the part of a) 
representing Griff C only. ..............................................................................................................59 
Fig. 19. Calcium Binding Protein 9kD mRNA expression in uterus of Wistar 
ovariectomised rats. Data represent means ± SD. *indicates a significant difference as 
compared to the vehicle-treated animals. ***p< 0.001 ..................................................................60 
Fig. 20. Progesterone Receptor and Vascular Endothelium Growth Factor mRNA 
expression in uterus of Wistar ovariectomised rats. Data represent means ± SD 
*indicates a significant difference as compared to the vehicle-treated animals.  
**p< 0.005, ***p< 0.001................................................................................................................61 
Fig. 21. Clusterin and Cyclooxygenase 2 mRNA expression in uterus of Wistar 
ovariectomised rats. Data represent means ± SD *indicates a significant difference as 
compared to the vehicle-treated animals. ** P< 0.005, ***P< 0.001 ............................................61 
Fig. 22. Insulin-like Growth Factor 1 mRNA expression in uterus of Wistar 
ovariectomised rats. Data represent means ± SD. * indicates a significant difference 
as compared to the vehicle-treated animals.*p<0.05 **p< 0.005 ..................................................62 
Fig. 23. Hepatic Clusterin and IGFBP-1 mRNA expression in Wistar ovariectomised 
rats. Data represent means ± SD. * indicates a significant difference as compared to 
the vehicle-treated animals. ** P< 0.005, ***P< 0.001. ................................................................63 
Fig. 24. Hepatic Carbonic anhydrase and Major acute protein gene expression in 
Wistar ovariectomised rats. Data represent means ± SD. * indicates a significant 
difference as compared to the vehicle-treated animals. * p< 0.05. ** P< 0.005. ...........................64 
Fig. 25. Hepatic Apolipoprotein A1 and Hepatic Nuclear Factor γ gene expression in 
Wistar ovariectomised rats. Data represent means ± SD. * indicates a significant 
difference as compared to the vehicle-treated animals. ** P< 0.005 *** P< 0.001. ......................64 
Fig. 26. ERα and PR mRNA expression in vena cava of Wistar ovariectomised rats 
Data represent means ± SD. *indicates a significant difference as compared to the 
vehicle-treated animals. *p< 0.05, *** p< 0.001............................................................................65 
Fig. 27. VEGF and VEGFR-2 mRNA expression in vena cava of Wistar 
ovariectomised rats. Data represent means ± SD. *indicates a significant difference as 
compared to the vehicle-treated animals. *P< 0.05, ** P< 0.005. .................................................66 
Fig. 28. ACE and NOS3 mRNA expression in vena cava of Wistar ovariectomised rats. 
Data represent means ± SD. * indicates a significant difference as compared to the 
vehicle-treated animals. *P< 0.05. .................................................................................................66 
Fig. 29. PCNA and Ki-67 expression in vena cava of Wistar ovariectomised rats. Data 
represent means ± SD. * indicates a significant difference as compared to the vehicle-
treated animals. ** P< 0.005. .........................................................................................................67 
Fig. 30. CLU and COX2 mRNA expression in vena cava of Wistar ovariectomised 
rats. Data represent means ± SD. * indicates a significant difference as compared to 
the vehicle-treated animals. *P< 0.001...........................................................................................67 
Fig. 31. Effect of 17β-oestradiol on Akt and phosphorylated Akt expression: 
Immunoblot of MCF-7 treated by E2 for 15 min. Lane 1: 10-10 M E2; Lane 2: 10-9 
M E2; Lane 3: 10-8 M E2; Lane 4: 10-7 M E2; Lane 5: 10-6 M E2..............................................68 
Fig. 32. Effect of Griff C on Akt and phosphorylated Akt expression: Immunoblot of 
MCF-7 treated by Griff C for 15 min. Lane 1: 10-10 M Griff C; Lane 2: 10-9 M Griff 
C; Lane 3: 10-8 M Griff C; Lane 4: 10-7 M Griff C; Lane 5: 10-6 M Griff C ..............................68 
Fig. 33. Regulation of Akt phosphorylation by PI3K inhibitor LY294002: Immunoblot 
of MCF-7 treated with vehicle (ethanol) or LY294002 for 15 min. C: control; LY25: 
25 mM LY294002; LY50: 50 mM LY294002...............................................................................69 
  List of figures 
 
 vii
Fig. 34. Effect of PI3K inhibitor LY294002 and oestrogen receptor antagonist 
fulvestrant on the phosphorylation of Akt induced by 17β-oestradiol and Griff C. 
MCF-7 breast cancer cells were treated with Griff C (10-6 M), E2 (10-8 M), 
LY294002 (50mM), fulvestrant (5x10-7 M), or both Griff C and LY50, or E2 and 
LY50, or Griff C and Fulvestrant, or E2 and fulvestrant for 15 min..............................................69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  List of abbreviations 
 
 viii
List of abbreviations 
 
µg Microgram 
µl Microliter 
1A Cytochrom-C-oxidase 
4-O-GIQ 4’-O-geranlisoliquiritigenin 
7-O-DHF 4’-methoxy-7-O-[(E)-3-methyl-7hydroxymethyl-2,6-
octadienyl]isoflavone  
7-O-GF 7-O-geranylformononetin 
7-O-GISO 3’,4’-dihydroxy-7-O-[(E)-3,7-dimethyl-2,6-octadienyl]isoflavone  
ACE Angiotensin converting enzyme 
AF-1 Activation function 1 
AF-2 Activation function 2 
AP-1 Activation protein 1 
ApoA-I  Apolipoprotein A1 
BSA  Bovine serum albumin 
BW Body weight 
C3  Complement component 3 
CA 2  Carbonic anhydrase 
CaBP 9kD Calcium Binding Protein 
cAMP Cyclic adenosine monophosphate 
CD1 Cyclin D1 
cDNA Complementary DNA 
CLU Clusterin 
COX 2 Cyclooxygenase 2 
dATP Deoxyadenosin triphosphat 
DBD DNA binding domain 
DCC Dextran-coated active charcoal 
dCTP Deoxycytidine triphosphate 
DEPC Diethyl pyrocarbonate 
dGTP Deoxyguanosin triphosphat 
DMEM Dulbecco's Modified Eagle's Medium 
DNA Deoxyribonucleic acid 
DNA Desoxyribonucleic acid 
dNTP Deoxynucleotide triphosphate 
DTT Dichlordiphenylschlorethan 
dTTP Deoxythymidine triphosphate 
E1 Estrone 
E2 oestradiol 
E3 estriol 
EDTA Ethylenediamin-N, N’, N’, N’ tetra acetic acid 
eNOS 3 Nitric oxide synthase 3 
ER Estrogen receptor 
ERE Oestrogen response element 
ERα Ostrogen receptor alpha 
ERβ Oestrogen receptor beta 
FCS Foetal calf serum 
g gram 
Griff C Griffonianone C 
  List of abbreviations 
 
 ix
Griff. E Griffonianone E 
Griff.C Griffinianone C 
H2O water 
HDL High density lipoprotein 
HNF-3γ Hepatic nuclear factor 3γ 
HPLC High Performance Liquid Chromatography 
HRP Horseradish peroxidase 
HRT Hormone replacement therapy 
IGF-1 Insulin growth factor 1 
IGFBP-1 Insulin-like Growth Factor Binding  
kD Kilo dalton 
Kg Kilogram 
LBD Ligand binding domain 
LDL Low density lipoprotein 
M Mole per litre 
MAP Major Acute phase Protein 
MAPK Mtogen activated protein kinase 
mg Milligram 
MgCl2 Magnesium Chloride 
ml Millilitre 
mM Millimol 
mRNA messenger-RNA 
NF-κB Nuclear factor κB 
NOS Nitric oxide synthase 
OD Optical density 
OECD Organisation for Economic Co-operation and Development 
OVX Ovariectomy 
PAGE Polyacrylamid gel electrophoresis 
PCNA Proliferating Cell Nuclear Antigen 
PCR Polymerase chain reaction 
pH Potential hydrogen 
PI3K Phosphatidylinositol 3 kinase 
PR Progesterone receptor 
RNA  Ribonucleic acid 
rpm rounds per minute 
SDS Sodium dodecyl sulphate 
SERM Selective estrogen receptor modulator 
SP1 Selective promoter factor 1 
TAE Tris-acetate + Na2-EDTA 
U Unit 
UV Ultraviolet 
VEGF Vascular endothelial growth factor 
VEGFR-2 VERGF-Receptor 2 
WHI Women's Health Initiative 
  Summary 
 
 x
Summary 
In most developing countries, a vast majority (70-80 %) of the population still resort to 
traditional medicine for their primary health care. Even in western countries, the search of 
alternative medication based on plant extracts is increasing at least among certain groups of 
people such as menopausal and postmenopausal women, and cancer patients. This medicine 
utilises medicinal plants, which are traditionally taken as aqueous extract. The root and 
stem bark of Millettia griffoniana Baill. (Fabaceae) has been reported to contain 
isoflavonoids, alkaloids, and diterpenoids. The possible benefit of some bioactive 
isoflavones derived from Millettia griffoniana prompted us to screen them for oestrogenic 
activity. Six isoflavones derived from Millettia griffoniana namely, 4’-methoxy-7-O-[(E)-3-
methyl-7hydroxymethyl-2,6 octadienyl]isoflavone (7-O-DHF), Griffonianone C (Griff C), 
7-O-geranylformononetin (7-O-GF), 3’,4’-dihydroxy-7-O-[(E)-3,7-dimethyl-2,6-
octadienyl]isoflavone (7-O-GISO), Griffonianone E (Griff E), 4’-O-geranylisoliquiritigenin 
(4-O-GIQ) were tested for potential oestrogenic activities in three different oestrogen 
receptor alpha (ERα) dependent assays. In a yeast based ERα assay, all test substances and 
17β-oestradiol as mammalian positive control, showed a significant induction of β-
galactosidase activity. The test compounds at the concentration of 5x10-6 M could achieve 
59 to 121 % of the β-galactosidase induction obtained with 10-8 M 17β-oestradiol (100%). 
For verification of the results, a reporter gene assay based on stably transfected MCF-7 cells 
(MVLN cells) was used. In this assay, isoflavones from Millettia griffoniana also 
stimulated the oestrogen receptor-dependent induction of luciferase. In Ishikawa cells, all 
substances exhibited oestrogenic activity revealed by the induction of alkaline phosphatase 
activity. The oestrogenic activities of isoflavones from Millettia griffoniana could be 
completely suppressed by the pure oestrogen antagonist, fulvestrant, suggesting that the 
compounds exert their activities through ERα. Although all substances showed oestrogenic 
effects, 7-O-DHF, Griff C, and 7-O-GISO were found to be the most potent of the tested 
substances. 
The expression of Ki-67, proliferating cell nuclear antigen (PCNA) and cyclin D1 (CD1) 
mRNA used as indicator of cell proliferation in MCF-7 cells was assayed. Griff C could 
induce a significant up regulation of the mRNA expression of both Ki-67and CD1 at  
concentrations of 10-8 M (for Ki-67) and 10-7 M. PCNA mRNA expression was not 
significantly up regulated by both Griff C and E2. 
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Based on these in vitro results, Griff C was further tested in vivo. The main objective of this 
part of the work was to study the mechanistic basis of the oestrogenicity of Griff C in rats. 
Female Wistar rats divided into five groups of six rats each were ovariectomised and a 
hormonal decline was allowed for 14 days. Three different doses of Griff C (2, 10, or 20 
mg/kg BW), and 17β-oestradiol (E2: 10 µg/kg BW) as positive control, and a vehicle 
control respectively were administered subcutaneously to ovariectomised rats. They were 
treated daily for three consecutive days and sacrificed 24 hours after receiving the last dose. 
The whole uterus was removed and weight. Liver and vena cava fragments were also 
collected and stored together with uteri in liquid nitrogen for subsequent real-time PCR to 
evaluate the effects of Griff C on the regulation of some relevant oestrogen–responsive 
genes. Griff C did not significantly affect the uterine wet weight. In contrast, 17β-oestradiol 
increased uterine wet weight 4.5 fold in comparison to the vehicle control. In contrats to the 
lacking proliferative response, Griff C affected expression of oestrogen-responsive genes in 
uterus, liver and vena cava of ovariectomised rats.  
Griff C decreased the expression of oestrogen receptors α (ERα) and β (ERβ) in the uterus. 
E2 induced a 551-fold stimulation of uterine complement C3 mRNA expression. Griff C at 
the dose 20 mg/kg BW caused a 50-fold up-regulation of C3 mRNA compared to the 
control. A significant increase in calcium binding protein 9 kilodalton (CaBP-9kD) mRNA 
expression was observed in the uterus of ovariectomised rats treated with E2 (41 fold versus 
control), 20 mg/kg BW of GriffC (25-fold versus control). In contrast, the expression of 
clusterin (CLU), progesterone receptor (PR), vascular endothelial growth factor (VEGF), 
cyclooxygenase 2 (COX 2), or insulin like growth factor 1 (IGF-1) in the uterus was 
strongly decreased by both E2 and Griff C at the highest dose tested. I also found a 
reduction of CLU, insulin like growth factor binding protein 1 (IGFBP-1), apolipoprotein A 
1 (ApoA-I) and hepatic nuclear factor 3 γ (HNF-3 γ) mRNA expression in the liver; while 
CA 2 and MAP mRNAs were slightly up-regulated. For the gene expression in vena cava, 
Griff C down regulated VEGF and ERα mRNA expression, whereas PR, Ki-67 and 
angiotensin converting enzyme (ACE) mRNA expression 
increased. The expression of PCNA and nitric oxide synthase 3 (NOS 3) mRNA remained 
unaffected by Griff C in the vena cava. 
The role of Griff C in apoptosis or in cell survival, through mediation of the 
phosphatidylinositol 3 kinase-Akt (PI3K-Akt) signalling pathway, was also investigated. 
Western blot analysis revealed that Griff C slightly increased the phosphorylation of Akt at 
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its serine 473 residue. The phosphorylation induced by Griff C was not inhibited by the 
specific ERs antagonist fulvestrant. 
In this work, oestrogenic properties of the isoflavones derived from Millettia griffoniana are 
described using reporter gene assays and the oestrogen-inducible alkaline phosphatase 
Ishikawa model for the first time. These in vitro data were verified in vivo showing the 
regulation of the expression of various relevant oestrogen-responsive genes by Griff C. The 
spectrum of its activity was clearly similar to that of 17β-oestradiol on uterine hepatic and 
vena cava tissues of ovariectomised rats except for the proliferative response. However 
Griff C remained 100 to 1000 times less effective than oestradiol. These findings confirmed 
that some of the biological effects attributed to Millettia griffoniana are closely related to 
oestrogen-mediated action. 
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1 Introduction 
1.1 current state of knowledge 
Advances in endocrine and medical researches in the past two decades or more has resulted 
into development of new treatment strategies for diseases highly associated with steroidal 
activity such as breast cancer, endometrial cancer, prostate cancer, osteoporosis and 
symptoms of menopausal disorders. One such strategy is the therapeutic use of sex steroid 
hormone, oestrogens to cure oestrogen deficiency symptoms occurring during menopause. 
Epidemiological studies support use of oestrogens in post-menopausal women for 
alleviation of uncomfortable menopausal symptoms such as hot flushes and for long-term 
prevention of diseases related to menopause, including osteoporosis and cardiovascular 
disease (Grodstein et al., 2000; Gruber et al., 2002). However, the exact role of sex steroid 
hormones in the development, progression or control of these diseases cannot be defined 
unless the mechanisms of action in normal tissues are understood.  
The effects of 17β-oestradiol on cell growth, differentiation, and general homeostasis of the 
reproductive and other systems, are mediated mainly by the regulation of temporal and cell-
type specific expression of different genes, whose products are molecules controlling those 
molecular events (Diel et al., 2002; Findlay et al., 2001; Hall et al., 2001). The interaction 
of oestrogens and progesterone with oestrogen receptors and progesterone receptors 
respectively, regulate gene transcription in a number of target tissues including the uterus, 
mammary gland, pituitary, brain, bone, liver and heart (Wu et al., 2003). 
Despite the advatanges, some studies have reported that the use of oestradiol for 
menopausal and postmenopausal women increases the cancer risk (Writing Group for the 
WHI, 2002; Million Women Study, 2002; Umland et al., 2000). Thus, there are efforts to 
find new compounds that exert selective effects by acting as antagonist on neoplastic or 
normal breast and uterine tissues, and as agonist on oestrogen-dependent tissues like bones, 
liver and central nervous system. Consequently, many plant-derived bioactive substances 
with considerable therapeutic benefits have attracted interest in the scientific community 
over the last two decades. Among these phytochemicals is the broad class of polyphenols 
including nonsteroidal oestrogens called phytoestrogens. The scientific interest lies in the 
potential of phytoestrogens for medical use like in hormone replacement therapy (HRT) 
either as registered drug or mostly as dietary supplement. Currently, certain plant 
derivatives are used in alleviation of menopausal symptoms like hot flushes, limitation of 
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bone resorption, or lowering cancer and cardiovascular disease risks (Umland et al., 2000). 
The use of certain plant derivatives might be related to their ability to bind oestrogen 
receptors and exert oestrogenic effects. Phytoestrogens display oestrogenic effects by 
binding to the oestrogen receptors (Morito et al., 2001). It might also provide selective 
actions on reproductive and non-reproductive oestrogen target tissues depending on the 
expression of ERα and/or ERβ. 
In most developing countries, 70-80% of the population still resort to traditional medicine 
for their primary health care. For instance, use of tradiotinal herbal medicine is popular in 
central Africa particularly Cameroon probably because of economic constraints related to 
the modern pharmaceuticals, and limited resource commited to health care services. 
However, there have been also notable increases in adoption of herbal medicine in the 
West. The reason has been mainly attributed to lower side effects of the treatments regimen.  
Most of the tradional medicines are traditionally taken as concoction of plant parts (eg. 
roots, stems and barks). One of plants highly utilised as medicine in Cameroon is Millettia 
griffonianna, which is taken as concoction of root and stem bark to treat certain ailments 
related to the metabolism of oestradiol. The root and stem bark of Millettia griffoniana has 
been reported to contain alkaloids (Kamgaing et al., 1994), diterpenoids (Ikan, 1969; 
Hanson, 1972), coumarines (Khalid and Waterman, 1983), flavonoids and isoflavonoids 
(Dagne et al., 1990; Dewick, 1994; Yankep et al., 1997; Yankep et al., 2001). Thus, the use 
of crude extract of Millettia griffoniana in the traditional medicine in east, central and west 
Africa, and the potential therapautic benefits of the isoflavones from Millettia griffoniana 
prompted us to investigate them for oestrogenic activities. As a result, some successful 
isoflavone candidate’s molecules from Millettia griffoniana without side-effect profile may 
be candidate molecules for development of alternative regimen to hormone replacement 
therapy. 
1.2 Aim of the study 
The main objectives of the study were to characterise compounds derived from Millettia 
griffoniana for potential oestrogenic properties. In the case, that for some compounds from 
Millettia griffoniana positive screening results can be obtained; the objective of the study 
would be extended to investigate the molecular mechanism by which the compounds exert 
their oestrogenic activities. In parallel, specific pathways suspected to be activated by 
compounds of interest were investigated in vitro. 
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1.3 Approach to the study 
To achieve the goal and objectives of the study, validated and reproducible in vitro 
bioassays were utilised to investigate and define the hormonal activity of isoflavones 
(Sohoni and Sumpter, 1998; Shelby et al., 1996; Zava and Duwe, 1997; Breinholt et al., 
1998). One screening assay and two independent in vitro bioassays were used to assess and 
to validate oestrogenic effects of some pure substances derived from Millettia griffoniana. 
The screening assay is capable of detecting low oestrogenic activities, (e.g. levels of 
oestradiol ranging between 0.1 to 1 nmol/l) (Petit et al., 1995). The first bioassay used was 
based on the oestrogen-induction of luciferase in MVLN cells expressing endogenous ERα. 
The second bioassay used was the endometrial Ishikawa model, which has been reported to 
produce a specific, natural and dose-dependent increase in alkaline phosphatase (AlkP) in 
response to oestrogens (Holinka et al., 1986).  
To investigate whether Griff C could significantly affect cell proliferation, I used MCF-7 
breast cancer cells to investigate the expression of PCNA, Ki-67, and CD1 genes which are 
proliferation markers induced in response to various signal including oestrogen stimulation. 
Although in vitro assays are good tools to investigate and to define the hormonal activity of 
chemicals, they cannot mimic the pharmacokinetic and pharmacodynamic interactions that 
likely influence the oestrogenic activity of substances in vivo. Therefore, in vivo assays 
were then conducted to verify the hypotheses generated in vitro.  
Thus, in the current study i have used the OECD (Organisation for Economic Co-operation 
and Development) recommanded and validated three days uterotrophic assay in 
ovariectomised wistar rats, one of the screening tests recommended for detecting and 
characterizing the oestrogenic properties of potential endocrine disrupting chemicals 
(OECD, 2001). I determined the uterotrophic potency of three different doses of Griff C and 
afterwards evaluated its action on the regulation of oestrogen–responsive genes in uterus, 
liver and vena cava, using real time PCR. 
To complete my investigation, i tested whether Griff C could mediate rapid intracellular 
signalling though the PI3K-Akt pathway. Immunoblotting was used to detect and measure 
relative amount of phosphorylated Akt and non-phosphorylated Akt in MCF-7 cells. 
1.4 Thesis outline 
This thesis document is divided into six chapters. The first chapter is the the introduction, 
which outlines the current state of knowledge, and identifies related gaps. The chapter 
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futher outlines the study working hypothesis, objectives and approach. The second chapter 
gives the background information and literature review on the the role of oestrogen’s in 
human and rat physiology as well as the cellular mechanism of action of oestrogens. The 
third chapter details the materials and methods used in the study. Chapter 4 and 5 are results 
and discussion repectively. Finally, conclusion, recommendation and new perspective of 
further research are detailed in chapter 6. Additional infomation and data used in the 
development of this thesis are appended. 
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2 Background and literature review 
This work sought to characterise functional properties of Millettia griffoniana used by 
cameroonian traditional practitioners to treat various deseases including those related to 
oestrogen deficiency. Therefore, the oestrogenic effects of isoflavones derived from this 
plant were investigated. In the present study, the oestrogenic potency of pure compounds 
from Millettia griffoniana were determined and compared to endogenous oestrogen and 
other substances, in in vitro and in vivo bioassays. Because these bioassays are based on the 
molecular and cellular mode of action of oestrogens, the role of oestrogen’s in human and 
rat physiology as well as the cellular mechanism of action of oestrogens are reviewed in the 
first part of this work. 
2.1 Oestrogens 
The most important naturally occurring oestrogens are 17β-oestradiol (E2), estrone (E1), 
and estriol (E3) (Fig.1). 
2.1.1 Synthesis of oestogens 
Oestrogens are steroid hormones derived from cholesterol by reduction of the number of 
carbon atoms from 27 to 18 under the control of the cytochrom P450 enzymes. In the last 
step in oestrogen formation, estrone and oestradiol are formed from their obligatory 
precursors androstenedione and testosterone, respectively. This reaction is catalyzed by the 
P450 aromatase monooxyygenase enzyme complex, which is present in the smooth 
endoplasmic reticulum and functions as demethylase. Estrone can be converted into 
oestradiol by 17β-hydroxysteroid dehydrogenase (17β-HSD) (Fig. 2). Estriol like estrone is 
primarily formed in the liver from oestradiol. 
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Fig. 1. Molecular structures of Oestradiol (1), estrone (2) and estriol (3) 
 
 
Fig. 2. Synthesis of oestradiol and estrone (adapted from: Production and actions of oestrogens, 
(Gruber, 2002) 
 
2.1.2 Endogenous sources of oestrogens 
E2, the most potent and important oestrogen in non-pregnant women, is predominantly 
produced in the ovaries by the granulosa cells of the active follicle and theca interna 
(Lieberman, 1996). Estrone and estriol are primarily formed in the liver from oestradiol. 
Aromatase activity resulting into the conversion of androgens to oestrogens has also been 
(3) 
2) (1) 
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detected in muscle (Matsumine et al., 1991), adipose tissues (Miller, 1991), nervous tissue 
(Naftolin et al., 1975), the Leydig cells of testis (Brodie and Inkster, 1993), skin, vaginal 
mucosa, endometrium, breast and liver (Murakami et al., 2001). In post-menopausal 
women, oestradiol is mostly formed by extragonadal conversion of testosterone (Gruber et 
al., 2002). During the reproductive period, the oestrogen production is under the control of 
gonadotropins, follicle stimulating hormone (FSH) and luteinising hormone (LH). 
 
2.1.3 Transport and metabolism of oestrogens 
In the serum 98% of E2 circulates bound reversibly and with either high affinity to sex-
hormone-binding globulin (Anderson, 1974), or less affinity to albumin in a nonsaturable 
and nonstoichiometric manner. Less than 10% of serum oestradiol is associated mainly with 
high-density lipoproteins (Tang et al., 1997), but serum oestradiol can also be transferred to 
low-density lipoproteins by an unknown carrier mechanism (Shwaery et al., 1997). 
Oestrogens are biologically inactivated by sulfation or glucuronidation, allowing renal 
excretion of the conjugated oestrogens. Although considerable amounts of inactivated 
oestrogens are excreted into the bile, only a small fraction appears in the faeces (Dötsch et 
al., 2001). Hydrolysis of these conjugates by the intestinal flora and subsequent 
reabsorption of the oestrogen result in an enterohepatic circulation (Gruber et al., 2002). 
Oestrogens are also metabolised by hydroxylation and subsequent methylation to form 
catechol and methoxylated oestrogens (Osawa et al., 1993). Fatty esters of oestrogens 
(lipoidal oestrogens) are synthesised in blood and stored predominantly in adipose tissue, 
which might serve as potential relevant steroid reserve. 
2.2 Physiological actions of oestrogens 
The physiological action of oestrogens is not only restricted to the control of the female 
reproductive system, oestrogens are also involved in male reproductive development and 
physiology, in bone and lipid metabolism and in the maintenance of the cardio-vascular and 
central nervous systems. The physiological actions of oestrogens in different organs are 
summarised in figure 3. 
 
2.2.1 Actions on the female reproductive system 
Oestrogens stimulate the follicular and endometrial growth in ovaries and uterus 
respectively. They are also involved in the cornification, the thickening and stratification of 
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epithelial cells in the vagina. The latter two responses are often assessed as physiological 
endpoint of oestrogen action in animal models. Oestrogen is a key regulator of the normal 
breast physiology as well as a major risk factor for breast carcinogenesis (Beral, 2003; 
Rossouw et al., 2002). In breast tissue, oestrogens stimulate the growth and differentiation 
of the ductal epithelium, induce mitotic activity of ductal cylindric cells, and stimulate the 
growth of connective tissue (Porter, 1974). A growth promoting effect was also observed in 
breast-cancer cells (Yue et al., 1999). 
 
2.2.2 Oestrogenic effects on the cardiovascular system 
Numerous studies have demonstrated that oestrogens have vasoprotective effects and 
therefore can lower the risk of developing cardiovascular disease; however, the Million 
Women Study has revealed that the HRT has no positive effect on the vascular deaseas 
(Million Women’s study, 2002). Oestrogens cause short-term vasodilatation by stimulating 
endothelial nitric oxide synthase. Nitric oxide plays an important role in vasodilatation 
(Kim et al., 1999). It also reduces vascular smooth-muscle tone by facilitating calcium flux 
though a mechanism that is dependent on cyclic guanosine monophosphate (White et al., 
1995). Several studies have demonstrated that oestrogens decrease low-density lipoproteins 
and increase high-density lipoproteins, which are cardio protective (O’Connell and Genest, 
2001; Libby, 2001). Oxidized LDL plays an important role in the ethiology of 
arteriosclerosis, and oestrogens inhibit this oxidation, which suggests that oestrogen 
treatment can reduce the progression of coronary-artery arteriosclerosis. However, there is 
still controversy on use of oestrogen treatment to prevent cardiovascular disease like 
arteriosclerosis in postmenopausal period (Grodstein et al., 2000). Oestrogens also inhibit 
apoptosis of endothelial cells (Spyridopoulos et al., 1997) and promote their angiogenic 
activity in vitro (Morales et al., 1995) 
2.2.3 Effects on bone 
The skeleton is one of the target tissues for sex steroids. Bone forms and remodels 
throughout life and the bone mass is reduced when osteoblastic bone formation diminishes 
relative to osteoclastic bone resorption. Oestradiol has a positive effect on bone mineral 
density by blocking bone resorption, which consequently reduces the risk of fracture in 
postmenopausal women and in those with osteoporosis. Both osteoclasts (Oursler et al., 
1991) and osteoblasts (Eriksen et al., 1988) express ERs, which makes them direct targets 
for oestrogens. Oestrogens directly inhibit the function of osteoclasts. Increased numbers of 
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bone-resorbing osteoclasts (Pacifici, 1996) primarily causes bone resorption following 
oestrogen depletion. Oestrogen therapy diminishes bone loss by stimulating the 
proliferation of osteoblasts so that the ratio osteoblasts/osteoclasts remain positive in favour 
of osteoblasts (Harmston et al., 2005). 
 
Fig. 3. Effects of oestrogens in different organ systems (from Gruber et al., 2002) 
2.3 Oestrogen receptors 
Oestrogen receptors (ER) are members of the superfamily of nuclear steroid/thyroid 
hormone receptors. Other members of this protein family are the receptors for testosterone, 
progesterone, corticoids, thyroid hormone, vitamins A and D3, and a large group of proteins 
referred to as ‘orphan’ receptors, for which specific ligands are still unknown (Horard and 
Vanacker, 2003). 
 
2.3.1 Discovery of oestrogen receptors 
Jensen and Jacosen (1962) first reported the existence of a protein that mediates the 
biological effects of oestrogen in 1962. In 1986, two research groups reported the cloning of 
the oestrogen receptor (ER) (Green et al., 1986; Greene et al., 1986). For about a decade, 
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the effects of oestrogen were believed to only be mediated by this receptor, until in 1996, a 
second ER, called ERβ, was cloned from rat (Kuiper et al., 1996), mouse (Tremblay et al., 
1997), and human (Mosselman et al., 1996). The human ERs are encoded by two distinct 
genes consisting of more than 140 kb of genomic DNA divided into 8 exons, and located on 
different chromosomes, 6q25.1 and 14q22-24.16 (Couse and Korach, 1999; Nilsson et al., 
2001). The former encodes for ERα, a 65 kD proteins made up by 595 amino acids (aa), and 
the latter encodes for two isoforms of ERβ, one of 55 kDa (485 aa) and another of 60 kDa 
(530 aa) (Enmark and Gustafsson, 1999). 
 
2.3.2 Structural and functional domains of oestrogen receptors 
All members of the nuclear receptor superfamily have a similar molecular structure 
consisting of six functional domains named A-F from N to C-terminus each capable of 
acting autonomously (Mangelsdorf et al., 1995). The structural and functional domains of 
nuclear receptors are:  
The N-terminal domain (domains A and B), that modulates transcriptional activation 
of target gene expression in a gene and cell specific manner through a ligand-independent 
Activation Function-1 (AF-1) (Berry et al., 1990, Tora et al., 1989); and This region of the 
receptor is also involved in protein-protein interactions (Onate et al., 1998). 
The most conserved domain between ERα and ERβ (95% of amino acid residues 
homology) is the central DNA binding domain (DBD).This domain consists of the C 
domain, which comprises two functionally distinct cystein-cystein zinc fingers through 
which ERs interact directly with the major groove and phosphate back bone of specific 
DNA, respectively (Kuiper et al., 1997; Schwabe et al., 1993). ER binding causes a bend in 
the DNA toward a major groove and facilitates the interactions of key transcriptional 
components. The specific DNA sequences to which both ERα and ERβ bind with high 
affinity are referred to as oestrogen response elements (ERE) (Klinge, 2000). The DBD also 
plays an important role in receptor dimerization. 
The hinge (D) domain contributes to the flexibility of the DNA- versus the ligand-
binding domain and might also serve as an anchor for certain corepressor proteins (Enmark 
and Gustafsson, 1999). 
The ligand binding domain (LBD) or domain E/F contains a ligand inducible 
Activation Function-2 (AF-2). This domain mediates ligand binding, receptor dimerisation, 
nuclear translocation, and transactivation of target gene expression (Evans, 1988, Tora et 
al., 1989). Crystallographic studies with the LBDs of ERα and ERβ revealed that the AF-2 
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interaction surface is composed of amino acids in helices 3, 4, 5, and 12 (Brzozowski, 1997; 
Pike et al., 1999) and that the position of helix 12 is altered by the shape of ligands and their 
binding. The positioning of helix 12 is the key event that permits discrimination between 
oestrogen agonists (E2 and DES), oestrogen antagonists (fulvestrant) and partial 
agonists/antagonists (raloxifen and tamoxifen) (Montano et al., 1995). 
 
Fig. 4. Schematic diagram of two human receptors, ERα and ERβ (adapted from Wenlin Shao and 
Brown, 2003). 
 
The overall degree of homology between ERα and ERβ is low; the ligand-binding domain 
has a 60% homology (Fig. 4). Both ERs differ most markedly (only 21% amino acid 
identity) in their N-terminal AF-1 domain. Ligand binding experiments have revealed high 
affinity, high specificity and low capacity of binding of oestradiol by ERβ, with a 
dissociation constant (Kd) similar to that of ERα, 0.6 nM (Enmark and Gustafsson, 1998). 
Human ERβ is approximately 89% identical to rat ERβ, 88% identical to mouse ERβ, and 
47% identical to human ERα (Enmark and Gustafsson, 1998). Rat ERβ protein is highly 
homologous to human ERα protein, particularly in the DBD (90% amino acid identity) and 
the C-terminal LBD (55%) (Kuiper et al., 1996). Additionally, several isoforms and splice 
variants of both oestrogen receptors have also been identified. They are common in breast 
cancer, and may interfere with the function of wild type ER or possess constitutive 
transcriptional activity (Fuqua et al., 1993a; Fuqua et al., 1993b). 
 
2.3.3 Distribution of oestrogen receptors 
In addition to the differences in the structure and ligand binding specificity, there are 
differences in the tissue distribution and functions of both ER subtypes. ERs are highly 
expressed in several human organs, both in reproductive and non-reproductive tissues (fig. 
5). In the female reproductive tissues, ERs are found in the ovary, uterus, endometrium and 
breast. In the ovary, the ERβ is localised to the stroma of the cortex as well as in the 
granulosa cells (Byers et al., 1997; Enmark et al., 1997). ERβ is less expressed in the uterus 
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than ERα and in breast, it is only expressed in the epithelium of the tubules (Enmark et al., 
1997). Both ERα and ERβ are present in the brain, but ERβ seems to be the main oestrogen 
receptor in the brain (Li et al., 1997). In the reproductive organs of the male, ERα is 
expressed in the Leydig cells of the testis (Fisher et al., 1997). ERβ is expressed in the testis 
and the prostate (Enmark et al., 1997). In rats, ERα expression is highest in uterus, testis, 
pituitary, ovary, kidney, epididymis and adrenal, whereas ERβ is most expressed in the 
brain, prostate, ovary lung, bladder and epididymis (Kuiper et al., 1996; Kuiper et al., 
1997). 
 
Fig. 5. Schematic representation of the major human tissues expressing ERα and ERβ in female 
(left) and male (right) (from Enmark and Gustafsson 1998). 
2.3.4 Regulation of oestrogen receptors 
The functional state and the cellular level of ERs are regulated in both normal and abnormal 
oestrogen-responsive tissues by various external signals. In most cases, the primary 
regulator is the endogenous ligand itself. For example, E2 in an auto-regulatory feedback 
loop mechanism can induce a decline in both ER protein and mRNA in the rat uterus 
(Nephew et al., 2000). Inhibition of ER synthesis was also reported in human breast cancer 
cells MCF-7, where E2 induced suppression of ER mRNA a few hours after treatment 
(Zhou et al., 1993). Additionally, inactivation of ERs by dephosphorylation might lead to 
the loss of their hormone binding capacity (Orti et al., 1992). E2 can also induce 
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degradation of ER though a proteasome-mediated pathway in both the pituitary and MCF-7 
cells (Alarid et al., 1999) 
2.4 Mechanism of Action of oestrogens. 
2.4.1 Classical gene regulatory pathway (for oestrogen action) 
The classical pathway for oestrogen action involves the activation of the oestrogen 
receptors as transcription factors. In the non-active state, ERs are located within the nucleus 
and the cytosol where they are prevented from dimerization, DNA binding, and interaction 
with coregulatory proteins by binding to heat shock proteins (HSP), immunophilins, and 
p23 (Pettersson and Gustafsson, 2001). After ligand binding, ERs undergo extensive 
conformational changes, which allow their dissociation from HSP, and the homo- or 
heterodimerization of ERs. Activated dimers diffuse into the nucleus and bind a specific 
DNA sequence named oestrogen response element (ERE), which is located within the 
promoter region of oestrogen target genes, and finally induce gene transcription.( Klinge, 
2000) 
2.4.1.1 Oestrogen Response Element  
The ERE was first identified, by aligning sequences with shared homologies in the 5’ 
flanking regions of the oestrogen-regulated vitellogenin genes A1, A2, B1,and B2 from 
xenopus laevis and the chicken VLDLII gene (Walker et al., 1984). Only a small number of 
the most oestrogen-inducible genes contain consensus EREs. They are commonly 
nonconsensus sites and exist as single, multiple full, or half sites. The ERE consists of a 
palindromic inverted repeat of six bases with a spacing of three variable bases, e.g. 
5’AGGTCAnnnTGACCT3’ (n representing any nucleotide) (Hyder et al., 1999; Klinge, 
2001), allowing the binding of the ER dimer in an antiparallel manner. Functional ERα or 
ERβ homodimers and ERα/ERβ heterodimers are able to bind to an identical ERE and 
induce gene expression. Interestingly, ERα homodimers appear to be less active than 
ERα/ERβ heterodimers (Cowley and Parker, 1999). However, the physiological relevance 
of this direct ERα/ERβ interaction remains unclear, since ERα and ERβ are partly expressed 
in the same tissue but not in the same cell type. Monroe et al (2005) have demonstrated that 
ERα/ERβ heterodimers can regulate ligand-dependent gene expression of genes not 
regulated by either ERα or ERβ homodimers in U2OS Osteosarcoma Cells (U2OS- 
ERα/ERβ cell line) or osteoblasts. 
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Through its binding to ERE, the activated oestrogen receptor complex recruits coregulators 
to the promoter through the concerted action of the AF-1 and the AF-2 domains. Activated 
ER-complexes bind to the TATA box within the gene promoter, and trigger the expression 
of specific mRNAs and the subsequent production of proteins that are responsible for the 
effects of the ligand (Wolffe, 1997). 
2.4.1.2 Coactivators and corepressors of oestrogen receptors 
Coactivators and corepressors are proteins that intercalate between the oestrogen-receptor 
complex and the transcriptional machinery (Fig. 6). The principal role of coactivators is to 
turn on target gene transcription, while corepressors inhibit gene activation and possibly 
turn off activated target genes (Chen and Evans, 1995; Chen et al., 2000). Steroid receptor 
coactivators such as SRC/p160 family of coactivators, TRAP/DRIP complexes, and 
CBP/p300 /cointegrators possess a receptor interacting domain (RID), which contains one 
or more LXXLL motifs (Heery et al., 1997). These motifs, where L is leucine and X is any 
amino acid, have been shown to mediate direct interaction with the AF-2 helix of nuclear 
receptors (Chen, 2000). Occasionally, some of these proteins have been found to associate 
with the AF-1 domain in the absence of any agonist. The exact mechanism that leads to 
stimulation of AF-1 activity has not been completely elucidated (Chen et al., 2000). On one 
hand, corepressor proteins interact directly with the agonist- or antagonist-occupied 
receptor, while on the other they also compete with steroid-receptor coactivator proteins. 
The Silencing Mediator of Retinoid and Thyroid Receptor (SMRT) protein and the Nuclear 
Receptor Corepressor (NCoR) are corepressors that contain repressive domains, which can 
associate with histone deacetylases (HDACs) and many other factors such as Sin3, to form 
a repression complex (Rosenfeld and Glass, 2001). This complex coordinates the 
deacetylation of histone molecules resulting in a condensation of chromatin and subsequent 
reduction in transcription (Lee et al., 2001). 
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Fig. 6. Diagram of the role of ER coregulators in gene transactivation (from Tremblay and Giguère, 
2002) 
 
2.4.2 ERE-independent pathways 
Besides the direct binding of the ER-ligand complex to the ERE sequence, ERα and ERβ 
can also modulate the expression of genes by interacting indirectly with DNA. In this way, 
ERα and ERβ act through binding to other DNA-bound transcription factors such as 
Activator Protein 1 (AP-1) transcription factors c-fos and c-jun (Paech et al., 1997; Webb et 
al., 1999), Sp1 (Porter et al., 1997) or NFκB (protein-protein interaction on DNA) (Nilsson 
et al., 2001) 
2.4.2.1 AP-1 pathway  
The mammalian AP-1 transcription factors are homo- and heterodimers composed of basic-
leucine c-Jun and c-Fos proteins subfamilies (Matthews et al., 2006). ERα and ERβ show 
opposite effects in regulation of AP-1 in an AF-1-dependent manner (Webb et al., 1999; 
Matthews et al., 2006). Anti-oestrogens induce activity of an AP-1 promoter in the presence 
of ERβ, whereas E2 blocks transcription. In the presence of ERα the pattern is reversed 
(Paech et al., 1997). Analysis of the mechanism of ERα-stimulated expression from an AP-
1 site showed that the agonist-bound ERα requires intact AF-1 and AF-2 functions and it 
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enhances AP-1 activity via interactions with the p160 family of coactivators. In contrast to 
the ERα activation, the ERβ activation with antiestrogens at AP-1/(CRE) targets is 
completely independent of the AF function (Webb et al., 1999). Partial oestrogen 
antagonists such as raloxifen interact with ERβ, leading to the recruitment of N-CoR or 
SMRT, which bind histone deacetylases (HDACs) and removed them from the AP-1 
regulated-promoter. Their removal results in the activation of transcription (Kushner et al., 
2000). 
2.4.2.2 SP1 pathway 
Additionally, other mechanisms of oestrogenic regulation of some genes associated with 
nucleotide biosynthesis and cell growth are regulated by the ERα-SP1 (protein-protein) 
interaction. This interaction occurs at oestrogen-responsive glutamine-rich promoter motifs 
of DNA (Safe, 2001; Porter et al., 1997). The SP family of transcriptions factors is 
characterised by a particular combination of three conserved Cys2His2 type zinc-fingers 
that form the sequence-specific DNA-binding domain (Kadonaga et al., 1987; Li et al., 
2004). The amino-terminal region of SP1 contains two serine- and threonine-rich domains 
and two glutamine-rich domains, which are essential for transcriptional activity (Courey et 
al., 1988). The carboxy-terminal domain of SP1 is involved in interactions with and 
synergistic activation by other transcription factors. SP1 can interact with many factors 
including the TATA-box-binding protein (TBP), which is a major component of the gene 
transcriptional machinery. Cofactors, CRSP are required for SP1 activation (Taatjes et al., 
2002). Other factors, such as co-activator p300/CBP (Billon et al., 1999) have also been 
reported to be associated with SP1. 
2.4.2.3 NF-κB pathway 
Another example of indirect action on DNA is the interaction of ERa with the subunit of the 
nuclear factor κB (NF-κB) complex. NF-κB is found in an inactive cytoplasmic complex 
with its inhibitor IκB inhibitory proteins. Phosphorylation of IκB by activated protein 
kinases results in its degradation, allowing NF-κB to move to the nucleus, where it binds to 
DNA and activates gene transcription. The NF-κB transcription factor is a coregulator that 
plays an important role in the induction of a wide variety of cellular genes (Lenardo and 
Baltimore, 1989). In addition to its role in inflammation and immune response, NF-κB has 
also been involved in the suppression of apoptosis (Wang and Marsden, 1996), cellular 
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survival, cell proliferation, differentiation, angiogenesis, and oncogenesis (Mercurio and 
Manning, 1999; Bharti and Aggarwal, 2002). 
 
2.4.3 Non genomic pathway 
The two ER subtypes, when bound to oestrogens can also regulate non-genomic mechanism 
of oestrogen action and therefore cause a rapid regulation of intracellular signalling 
pathways through protein-protein interactions. Activated protein kinases phosphorylate 
other downstream kinases which finaly activated effective proteins. Such rapid non 
genomic effects have been described in several mammalian tissues and cell types such as 
bone, neuronal, mammary, ovarian and cardiovascular cells (Belcher and Zsarnovszky, 
2001; Gray et al., 2001; Coleman and Smith, 2001). There, oestrogens have been shown to 
activate distinct intracellular signalling pathways such as protein kinase A (PKA), mitogen-
activated protein kinase (MAPK), and PI3K/Akt pathway (Honda et al., 2000). Other rapid 
effects induced by oestradiol are the stimulation of endothelial nitric oxide synthase (eNOS) 
(Chen et al., 1999), and the increase of intracellular Ca2+ fluxes (Kelly and Levin, 2001; 
Levin, 2001). Many of these oestrogen-stimulated pathways are typically initiated at the 
plasma membrane (Fig. 7). Recent studies with E2 conjugated to BSA (Kelly and Levin, 
2001; Kuroki et al., 2000; Watters et al., 1997) or to fluorescent macrocomplexes (Berthois 
et al., 1986), have demonstrated that there are cell membrane-localized ERs, which may be 
responsible for the rapid non-genomic action of oestrogens. Indeed, some recent reports 
suggest that this membrane oestrogen binding protein and nuclear ER may be derived from 
the same single transcript (Razandi et al., 1999). However, the precise nature of this 
membrane ER remains elusive. 
2.4.3.1 Phosphatidylinositol 3-kinase (PI3K)-Akt Pathway 
The PI3K pathway is one of the key signals downstream of oestrogen receptor, which 
activates antiapoptotic Akt signalling (Dery et al., 2003). The serine/threonine kinase (Akt), 
also known as protein kinase B (PKB), is the cellular homologue of the viral oncogen ν-
Akt. The Akt protein contains a NH2-terminal pleckstrin homology domain, which can bind 
to the phosphorylated lipids generated by the activity of PI3K and translocate Akt to the cell 
membrane (Franke et al., 1995). There Akt is activated by the membrane-associated kinase 
(PDK1), which phosphorylates Akt at threonine 308 or serine 473 residues in response to 
growth factors and cytokines (Alessi et al., 1996; Vanhaesebroeck and Alessi, 2000). 
Phosphorylated Akt is an important regulator of multiple biological processes, including the 
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reduction of apoptosis, cell survival, the cell cycle, and glucose up-take (Scheid and 
Woodgett, 2001; Nicholson and Anderson, 2002). Oestrogens are also involved in the Akt 
activation (Hisamoto et al., 2001). This finding is highlighted by the recent discovery that 
oestrogen-bound ERα associates with the regulatory subunit of phosphatidylinositol 3-
kinase (PI3K), resulting in the activation of the Akt serine/threonine kinase and endothelial 
nitric acid synthase in endothelial cells (Simoncini et al., 2000). 
2.4.3.2 Mitogen activated protein kinase (MAPK) pathway  
Many nongenomic effects of E2 might be mediated by p44/p42 MAPK, also known as 
(ERK)-1/2. The role of ERα in the MAPK signalling cascade has been demonstrated 
previously. Activation of extracellular signal-regulated kinase (ERK)-1/2 has been observed 
in colon cancer (Di Domenico et al., 1996), breast cancer (Castoria et al., 1996), rat 
cardiomyocytes (Nuedling et al., 1999) and bone (Endoh et al., 1997), leading to responses 
including cell growth (proliferation), cell cycle progression, and survival. 
 
Fig. 7. Selected non-nuclear and nuclear activities of ERα (Ho and Liao, 2002) 
 
2.4.4 Oestrogen-independent pathways  
The activity of ERs can mediate the expression of some ER target genes in the absence of 
oestradiol. Indeed the best example of this mechanism of non-nuclear E2-stimulation is 
provided by the activation of ERα by epidermal growth factor (EGF) and IGF-1. Through 
this cross-talk mechanism, mitogenic extracellular signals are translated into cell cycle 
progression or, in cancer cells, into proliferation in the absence of hormone (Kato et al., 
2000). ERα is directly phosphorylated on serine 118 by activated MAPKs (Endoh et al., 
1997; Bunone et al., 1996; Kato et al., 1995). This phosphorylation of ERα enhances the 
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binding of p68 RNA helicase (Endoh et al., 1999), resulting in an enhancement of AF-1 
transcriptional activity in uterine and ovarian cells (Ignar-Trowbridge et al., 1993; Ignar-
Trowbridge et al., 1996). In addition to direct phosphorylation of the receptor, EGF can also 
modulate the ERK-1/2 –mediated phosphorylation of SRC-1, which exponentiates ERα 
transcriptional activity (Rowan et al., 2000). 
2.5 Oestrogen antagonists or antiestrogens 
Antiestrogens are compounds that inhibit oestrogen action by competing for the oestrogen 
receptors (Dauvois et al., 1993). They are classified according to their mechanisms into two 
basic types, type I or partial (agonistic/antagonistic), and type II or pure antagonists. 
 
2.5.1 Selective oestrogen receptor modulator (SERM) 
The term “selective oestrogen receptor modulator” (SERM) was introduced to define 
nonsteroidal ligands that antagonize the action of oestrogens in some target tissues, and 
mimic its actions in some others. Most of these compounds are analogues of tamoxifen and/or 
its metabolites, 4-hydroxy-tamoxifen (Jordan et al., 1977). They bind ERs, interact with EREs 
and exert their antioestrogenic effect by inhibiting the activity of the transcriptional factor 
AF-2, but not of AF-1, which remains active (Berry et al., 1990; Katzenellenbogen, 1995). 
Therefore, SERMs like tamoxifen have the potential to act as an antagonist when the 
transcriptional activity of the receptor is mediated by AF-2 but as agonist on promoters or in 
cell types where AF-1 is active. Additionally a third site of activation termed AF-2a was 
described recently, which can function when AF-1 and AF-2 are inactive (Norris et al., 1997). 
The conformational changes in ERs upon oestrogen agonist binding, allow a hydrophobic 
cleft made up of Helix 3, 5 and 12 to form on the surface of the ligand binding domain. This 
cleft is the docking surface for coactivators. The binding of antagonists to ERs instead 
displaces helix 12 from its normal position into the hydrophobic cleft, thereby occluding the 
cleft from coactivators (Shiau et al., 1998). 
The mechanism of action of SERMs is complex considering the differential binding of 
antiestrogens to transcriptional activation factors, depending on the compounds’ 
concentration, with AF-2 having the highest affinity. For example, tamoxifen in a low 
concentration blocks AF-2, while at high concentrations; it inhibits the ER action by totally 
blocking both AF-1 and AF-2 (Hedden et al., 1995). There is strong evidence that part of the 
mechanism of antagonism might be a result of the recruitment of corepressors (Horwitz et al., 
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1996; Jackson et al., 1997). The lack of AF-2 activity in the presence of either type of 
antiestrogen is likely due to the incorrect alignment of helix 12, leading to its inability to form 
an appropriate surface for the binding of coactivator proteins. A number of other non-
steroidal antiestrogens, derived from tamoxifen, with a spectrum of activities similar to that of 
tamoxifen, have been described in the literature, including toremifene, droloxifene, idoxifene, 
raloxifene, and EM-800. The possible cross-resistance between tamoxifen and its derivatives 
might limit the use of tamoxifen derivatives in patients with advanced disease after adjuvant 
tamoxifen treatment (Stenbygaard et al., 1993; Buzdar et al., 1988; Stein et al., 1990). 
 
2.5.2 Pure oestrogen antagonists/ antioestrogens 
Several compounds with the appropriate pure antagonist effects were discovered within the 
past two decades (Wakeling and Bowler, 1987; Bowler et al., 1989). Among these 
substances, fulvestrant, 7α-[9-(4,4,5,5,5-pentafluoro-pentyl-sulphinyl)nonyl]oestra-
1,3,5(10)-triene- 3, 17 β diol was reported to be the most potent. Fulvestrant is a derivative 
of oestradiol with a long hydrophobic side chain at the 7α-position (Fig.8) and was 
developed as an antagonist which binds to oestrogen receptors with high affinity without 
activating any of the normal transcriptional hormone responses (Howell et al., 2000). In 
contrast to SERMs, fulvestrant blocks ER transactivation regulated by both AF-1 and AF-2 
(Wakeling, 1995). There is evidence that fulvestrant might also impair the dimerization of 
the receptors (Fawell et al., 1990) but most importantly, it induces ER degradation by a 
proteasome mediated mechanism, thereby reducing the cellular concentration of ER 
(Dauvois et al., 1993). As a consequence of these cellular effects, fulvestrant is a potent 
inhibitor of the transcription of oestrogen regulated genes. 
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Fig. 8. Chemical structure of fulvestrant. 
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2.6 Oestrogen disruptors/environmental oestrogens 
Numerous compounds found in the environment can mimic oestrogen action (agonistic 
effect) or interfere with the synthesis, storage, release, transport, elimination, binding, or 
action of endogenous hormones. Environmental oestrogens might have some beneficial 
qualities or might simply cause reproductive and developmental disorders (Colborn et al., 
1993). These compounds include mycoestrogens, synthetic oestrogens, and natural plant 
chemicals named phytoestrogens. 
 
2.6.1 Xeno-oestrogens 
Xenobiotic chemicals (“xeno-oestrogens”) that have been shown to mimic oestrogens, 
include the organochlorine pesticide o,p’DDT, the industrial surfactant 4-nonylphenol, 
plasticizers such as di-(2-ethylhexyl)phthalate (DEHP) and Bisphenol A, herbicides and 
detergents (Hammond et al., 1979; McLachlan et al., 1984; Nagel et al., 1997). 
 
2.6.2 Synthetic oestrogens 
These compounds are mostly pharmaceuticals specifically synthesised to mimic oestrogens 
effects (actions). They include compounds like ethinylestradiol, the anti-conception pill 
component; diethylstilbestrol; Propylpyrazoltriol (PPT) and ZK281738, ERα-selective 
agonists; Diarypropionitril (DPN) and ZK281471, ERβ-selective agonists, estren and many 
others. 
 
2.6.3 Phytoestrogens 
Plants extracts were already reported to exhibit oestrogenic activity in 1927 (Loewe et al., 
1927). By 1975, several hundred plants have been found to exhibit oestrogenic activity in 
bioassays due to oestrogenic compounds termed later phytoestrogens (Farnsworth et al., 
1975). Phytoestrogens gained biological and economic relevance in the 1940s, with the 
outbreak of infertility in sheep grazing on pastures rich in subterranean clover in Western 
Australia, later known as “Clover Disease” (Bennetts et al., 1946). 
Phytoestrogens are defined as plant-derived compounds of non-steroidal structure with 
oestrogenic or antioestrogenic properties (Umland et al., 2000). Plants in response to 
exterior aggressions primarily produce Phytoestrogens. In that case they might act as 
fungicides, deter herbivores, regulate plant hormones, and protect against ultraviolet 
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radiation (Naim et al., 1974; Hughes, 1988). They are found in a variety of plants consumed 
by humans, including fruits and vegetables, but are most abundant in legumes. For example, 
several plants such as soy, flax, red-clover, hops, citrus, grape, black cohosh, dong quai, 
ginseng, licorice, and wild Mexican yam (Umland et al., 2000), have been shown to possess 
phytoestrogens. Most phytoestrogens are found as glycosides in plants (Allred et al., 2001). 
Phytoestrogens bind the human oestrogen receptor with an affinity 10-1000 fold lower than 
oestradiol (Morito et al., 2001). They compete with oestradiol for the receptor site and 
therefore can act as agonists or antagonists (Verdeal, 1980). Data from epidemiological 
surveys and nutritional intervention studies indicate that some phytoestrogens ameliorate 
menopausal symptoms, and are protective against a variety of disorders, including 
cardiovascular disease, cancer, hyperlipidemia, osteoporosis and various forms of chronic 
renal disease (Adlercreutz and Mazur, 1997; Setchell et al., 1998; Tham et al., 1998; Lissin 
and Cooke, 2000; Ranich et al., 2001). Phytoestrogens, after absorption, undergo 
enterohepatic circulation, and they are conjugated to glucuronic acids in the liver and 
excreted in urine (Knight et al., 1996) smaller amounts are excreted as sulfates and 
sulfoglucuronides; (King, 1996). Phytoestrogens encompass several classes of compounds 
including isoflavones, coumestans and lignans (Mazur et al., 1998; Miksicek, 1995; Knight 
and Eden, 1995; Clarke et al., 1996). 
2.6.3.1 Isoflavones 
Isoflavones have a 3-phenyl-4H-benzopyran 4-one (or a 2 phenylnaphthalene) chemical 
structure (Fig. 9) similar to that of oestradiol (Setchell, 1998). The substitution at various 
positions on the rings with additional chemical groups modulates the ability of isoflavones 
to act as phytoestrogens by fitting into the pocket representing the binding domain on 
oestrogens receptors. Therefore, isoflavones have been reported to share many of the 
properties of endogenous oestrogens (Morito et al., 2001). Numerous research works have 
shown that isoflavones like genistein and daidzein have multi-biological and 
pharmacological effects in animals and humans. (Umland et al., 2000; Bhathena and 
Velasquez, 2002). They might act as agonist or antagonist of oestrogenic action, influence 
cell signalling as well as cell growth and death. Isoflavones also regulate gene transcription, 
modulate transcription factors, act as antioxidants (Brownson, 2002, Kavanagh, 2001), as 
well as inhibit enzymes like tyrosine kinase, thyroid peroxidase and DNA topoisomerases I 
and II (Akiyama et al., 1987; Knight et al., 1996). The main sources for isoflavones are soy 
products, beans, peas, nuts, grain products, coffee, tea and certain herbs such as red clover 
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(Setchell, 1998). The major soy isoflavones, genistein and daidzein, commonly exist in 
plants as glucoside-bound complexes that are biologically inactive (daidzin, genistin and 
glycitin) (Axelson et al., 1984; Knight et al., 1996). Isoflavones might have some health 
benefit properties such as preventing certain cancers (Messina and Loprinzi, 2001), 
lowering the risk of cardiovascular diseases (Anderson et al., 1995) and limiting bone 
resorption (Arjmandi et al., 1996). 
 
O
O
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HO  
Fig. 9. General structure of isoflavones 
 
2.6.3.2 Flavonoids 
Flavonoids are diphenolic compounds, which are present in high concentrations in whole 
grains, legumes, fruits and vegetables (Le Bail et al., 1998). They also exert oestrogenic 
activity, although at a much lower level of activity compared to isoflavonoids (Miksicek, 
1993; Breinholt and Larsen, 1998; Collins-Burow et al., 2000). Moreover, some flavonoids 
like kaempferol and quercetin exhibit antioestrogenic activities (Collins-Burow et al., 2000). 
Naringenin and hesperetin are flavonoids found in higher amounts in citrus fruits (Breinholt 
et al., 2004). 8-prenyl Naringenin is the most potent phytoestrogen discover so far. It is found 
mostly in hops (Schaefer et al., 2003). 
2.6.3.3 Lignans 
Lignans are more prevalent in the plant kingdom but their oestrogenic properties are lower 
compared to isoflavones. The oestrogenic active lignans, enterodiol and enterolactone, are 
produced by bacteria in the colon from secoisolariciresinol and matairesinol respectively 
(Adlercreutz, 1990). 
2.6.3.4 Coumestans 
Coumestrol is the most important coumestan consumed by humans. It is found at high 
concentrations in clover and alfalfa sprouts, but also at lower concentrations in sunflower 
seeds, lima bean seeds, pinto bean seeds, and round split peas (Franke et al., 1995). 
  Background and literature review 
 
 24
2.7 Millettia griffoniana 
2.7.1 Botanical studies/distribution 
Millettia griffoniana (Baill.) is a plant belonging to the large family of Fabaceae (sub-family 
of papillionoidae). The genus Millettia is composed of about 200 species of trees, shrubs, and 
climbers widely spread in the tropical zones of Africa (Irvine, 1961), Asia, Australia, and 
America (Thulin, 1983). Millettia griffoniana is a shrub of about 3m that grows along rivers 
in the undergrowth of the rainforest of central and northwest provinces of Cameroon 
(Mbenkum, 1986). 
2.7.2 Description of plants of the genus Millettia 
The plants of the genus Millettia are identifed based on some morphological and macroscopic 
characteristics, which include leaves alternate, pinnately (or twice pinnately) compound, to 
palmately compound, trifoliolate. They also have stipules, which are inconspicuous to 
leaflike. Inflorescences usually indeterminate, sometimes reduced to a single flower, terminal 
or axillary; flowers are usually bisexual, radial to bilateral, with a short, usually cup-shaped. 
In contrast to other species, the flowers of Millettia griffoniana, which appear in July-August, 
hang under “branches”, forming a purplish-rosy (purple to pink) curtain. The leaves of 
Millettia griffoniana are small (8x3 cm) and do not have the “nervation” of other Millettias; 
they also have 3-4 pairs of leaflets. Fruits are woody pods (8 x 2.5 cm) covered with a thick 
layer of brown hair (Judd et al., 1999). 
2.7.3 Phytochemistry/active constituents 
The main constituents in plants of the genus Millettia have been determined to be alkaloids, 
diterpenoids, coumarines, flavonoids and isoflavonoids. Previous phytochemical studies 
carried out by Yankep et al (1997; 1998; 2001), described the isolation and structural 
elucidation of a chalcone, a rotenoid, a phenylcoumarine, and several isoflavones. All these 
compounds were isolated from the hexane and chloroform extracts of root bark from of 
Millettia griffoniana. Additionally, new prenylated isoflavonoids (griffonianone F, G, and H) 
have recently been isolated from seeds of Millettia griffoniana by Ngamga et al (2005b). The 
new compounds exhibit moderate trypanocidal and anti-plasmodial activities (Ngamga et al, 
2005a). 
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2.7.4 Traditional use and application of Millettia griffoniana 
Many members of the genus Millettia have been reported to possess insecticidal, piscicidal, 
and molluscicidal properties (Teesdale, 1954; Singhal et al., 1982). Some plants like Millettia 
conraui, Millettia laurantii and Millettia sanagana are used for the treatment of intestinal 
parasites and colics in children (Singhal, 1982). Millettia zechiana is used for the treatment of 
bronchial and rhinopharyngial ailments. 
Crude extracts from root and stem bark of Millettia griffoniana are used in traditional 
medicine in some village communities of Cameroon to treat boils, insects bits, 
inflammatory affections like pneumonia and asthma, infertility, amenorrhea and 
menopausal disorders (Sandberg and Cronlund, 1977). It was reported recently that 
Griffonianone D, an isoflavone from root bark of Millettia griffoniana, possesses anti-
inflammatory activities in induced-oedema rats and mice (Yankep et al, 2003). Several 
studies in chinese traditional medicine show ameliorating effects of Millettia nitida, called 
“ji xue teng”, in the treatment of cardiovascular diseases, liver fibrosis, rheumatoid arthritis, 
sciatica, inflammation, cancer, and skin diseases (Ping et al, 1997; Zhang, 2000; Xu et al., 
1997). There is also evidence that Millettia nitida can be protective against leukopenia 
induced by radiation therapy and it has uterus stimulating and analgetic properties (Ping et 
al., 1997; Zhang, 2000). However, in many of these studies, Millettia is only part of a lager 
formula, so the specific role of Millettia in these treatments remains unclear (Ping et al., 
1997; Zhang, 2000). Although some plants of the genus Millettia are commonly used for 
the treatment of various conditions, their hormonal, particularly oestrogenic or 
antioestrogenic properties have no yet been described in the literature. 
2.8 Oestrogen-responsive genes used as marker genes 
2.8.1 Cytochrom C oxidase (1A) 
Cytochrome C oxidase is the terminal enzyme in the respiratory system of most aerobic 
organisms where it catalyzes the sequential four-electron transfer (ET) from cytochrome c to 
dioxygen (Ferguson-Miller and Babcock, 1996). This enzyme is composed of 13 subunits. 
The mitochondrial genome encodes the three largest subunits (I, II, and III) and the other 10 
subunits are encoded by nuclear DNA (Cooper et al, 1991). The subunit I is the largest most 
functional subunit of the holoenzyme and is the only subunit conserved from prokaryotes to 
eukaryotes (Rottenberg, 1998). 
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2.8.2 Proliferating cell nuclear antigen (PCNA) 
The proliferating cell nuclear antigen (PCNA) is a nonhistone intranuclear protein that 
serves as a cofactor for polymerase delta during the DNA synthesis of the cell cycle (Bravo 
et al., 1987). Since PCNA is synthesised in the early G1 and S phases of the cell cycle and 
is associated with DNA synthesis (Hall et al., 1990), its detection both at the mRNA and 
protein levels is used to measure cell proliferation (Calaf et al., 2005). The expression of 
PCNA can be regulated by oestrogen (Lobenhofer et al., 2002). 
 
2.8.3 Ki-67 
The Ki-67 protein was originally defined by the interaction with the prototype monoclonal 
antibody Ki-67 (Gerdes et al., 1983), which was generated by immunising mice with the 
nuclei of the Hodgking lymphoma cell line L428. Since this protein is expressed in all 
proliferating cells, including normal and tumour cells, it is used as an excellent marker of the 
cell proliferation (Nnene et al., 2004; Stygar et al., 2003). Ki-67 is expressed in the nuclei of 
cells in the G1, S, and G2 phases of the cell division cycle as well as in mitosis, and not 
expressed in quiescent or resting cells in the G0-phase (Stygar et al., 2003; Gerdes et al., 
1984). The functional role of the Ki-67 protein during cell proliferation remains unknown. 
2.8.4 Cyclin D1 (CD1) 
Cyclin D1 was discovered in parathyroid carcinoma (Motokura and Arnold, 1993). CD1, a 
member of the G1 cyclins, is a major positive regulation for the cell cycle progression from 
G1 to S phases (Baldin et al., 1993). Cyclin D1 is known as the major target of mitogenic 
signals and it is continuously synthesised as long as mitogenic stimulation continues, and 
rapidly degraded when mitogens are withdrawn (Matsushime et al., 1991). D-type cyclins 
associate with cyclin D kinases to promote cell cycle progression (Reed, 1997). 
 
2.8.5 Complement component 3 (C3) 
The complement C3 is a component of the complement system, which consist of more than 
20 plasma and cell membrane associated proteins. C3 is the common intersection of the 
complement pathways (classical-, alternate, and lectin pathways). Activation of these 
pathways results in induction of the inflammatory response, phagocyte chemotaxis and 
opsonization, and cell lysis (Ogden and Elkon, 2006). Although C3 is synthesised mainly in 
hepatocytes, (Alper et al., 1969), other cells also synthesise complement components, 
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including renal cells, monocytes, macrophages (Johnson and Hetland, 1988; Whaley, 1980), 
fibroblasts (Katz and Strunk, 1988), endothelial cells (Warren et al., 1987), osteoblastic cells 
(Hong et al., 1991) and epithelial cells (Strunk et al., 1988). Fan et al (1996) have identified 
three functional EREs in the human C3 gene-promoter and in the uterus of rat and mice the 
gene is strongly up-regulated in response to oestradiol (Li et al., 2002; Brown et al., 1990). 
2.8.6 Calcium binding protein 9 kilo Dalton (CaBP 9kD) 
Calcium binding protein 9 kilo Dalton is mainly expressed in intestine, uterus and lungs of 
adult rats. This protein is considered to regulate intracytoplasmic concentration and transport 
of free calcium ions. An ERE involved in the regulation of CaBP 9kD by E2 has been 
characterised (Darwish et al., 1991; L’Horset et al., 1994). 
2.8.7 Progesterone receptor (PR) 
Progesterone receptors are intracytoplasmic proteins that bind to progesterone and play an 
important role in the regulation of many female reproduction processes. PRs are involved in 
the regulation of ovulation (Rondell, 1974) and luteinization (Park and Mayo, 1991) in the 
ovary. They also influence the implantation of embryos in the uterus and the maintenance of 
pregnancy (Zhang et al., 1997). PRs are expressed in the uterus by both stromal and epithelial 
cells (Ohta et al., 1993). Although the mechanism of the cell-specific regulation of PR by 
oestrogen remains to be elucidated, oestrogen has been shown to induce PR in the stromal and 
glandular cells, whereas it is reduced in luminal epithelial cells (Paech et al., 1997). 
2.8.8 Vascular endothelial growth factor (VEGF) and VEGF-receptor 2 (VEGFR-2) 
Vascular endothelial growth factor is a secreted mitogen, which plays an important role in the 
regulation of angiogenesis and vascular permeability (Leung et al., 1989; Neufeld et al., 
1999). VEGF exerts its function through the phosphotyrosine kinase receptors VEGF 1 and 2 
(Matsumoto and Claesson-Welsh, 2001; Neufeld et al., 1999). Both VEGF mRNA and 
protein are up regulated in astrocytes and inflammatory cells in neuronal lesions; 
concomitantly VEGF 1 and 2 were also expressed in the vessels which border these regions 
(Skold et al., 2005). 
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2.8.9 Clusterin (CLU) 
Clusterin, also called Testosterone-repressed Protein Message-2, Sulfated Glycoprotein-2 or 
Apolipoprotein J (ApoJ) is a heterodimeric, highly glycosylated protein composed of 449 
amino acid residues, with an apparent molecular mass of 75-80 kD. This protein consisting of 
two subunits a, and b of 40 kD linked by a unique five-disulfide-bond motif (Blaschuk et al., 
1983), is encoded by a gene localized on the chromosome 8. CLU is widely expressed in 
different tissues including uterus, brain, ovary, testis and liver, where it plays an important 
role in remodelling damaged tissues and in tissue reorganisation during embryonic 
development (French et al., 1993). It is abundant in numerous biological fluids like semen, 
urine, breast milk, plasma and cerebrospinal fluid (Aronow et al., 1993). CLU is thought to be 
involved in various biological processes including spermatogenesis, lipid transport, immune 
regulation, and apoptosis (Jenne and Tschopp, 1992; May and Finch, 1992; Tenniswood et 
al., 1992). The gene controlling the regulation of the expression of CLU contains in the 
promoter region numerous possible binding motives like two AP-1 binding domain, one AP-2 
binding motive, eight halfsites of glucocorticoid/androgen response element, and a cAMP-
responsive element (Rosemblit and Chen, 1994; Wong et al., 1993). A strong oestrogen-
dependent regulation of the clusterin mRNA-expression has been reported in rat uterus (Diel 
et al., 2000), in rat lymph nodes (Zierau et al, 2004b), in Ruca-I cells (Zierau et al., 2004a) 
and in endometrial oestrogen-dependent carcinoma (Wunsche et al., 1998). 
2.8.10 Cyclooxygenase 2 (COX 2) 
Cyclooxygenase, also called prostaglandin syntase, is a bi-functional enzyme that converts 
arachidonic acid to prostaglandins, which are biologically active proteins that play an 
important role of mediators in the implantation of embryos (Lim et al., 1999). These proteins 
are also associated with inflammation, fever, pain, and tissue injury. Moreover, they have 
mitogenic and tumour-promoting properties but are also required for normal physiological 
functions, in the gastrointestinal, the renal, and the immune system, and during reproduction, 
growth, and development (Dubois et al., 1998). COX exists in two distinct isoforms: one 
constitutive isoform COX 1 and an inducible isoform COX 2 (Vane et al., 1998). The former 
is associated with gastric cytoprotection, platelet function and cellular homeostasis, while the 
latter is associated with inflammation and cell proliferation (Marnett and Kalgutkar, 1999). 
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2.8.11 Insulin like growth factor 1 (IGF-1) 
Insulin-like growth factor 1 is a peptide that binds to the transmembrane tyrosine kinase 
receptor and induces a series of phosphorylation events such as the MAP Kinase cascade 
(Rubin and Baserga, 1995). Like oestrogen, this factor is a potent mitogen involved in a 
large array of processes that control proliferation and differentiation of mammalian cells 
(Katzenellenbogen, 1996). Interactions between E2 and IGF-1 have been demonstrated in 
the central nervous system, in various reproductive tissues and in cell culture (Pons and 
Torres-Aleman, 1993; Wimalasena et al., 1993; Sahlin et al., 1994; Stoica et al., 2000). 
IGF-1 is also a non hormonal inducer of oestrogen action. 
 
2.8.12 Insulin like growth factor binding protein 1 (IGFBP-1)  
Insulin-like growth factor binding proteins 1 is produced mainly by the liver, kidney and 
decidua (Coverley and Baxter, 1997). IGFBP-1 is a member of six circulating IGFBPs that 
prolong the half-life of IGF-1 and play therefore an important role in controlling the IGF-1 
availability and effects on target tissues (Koistinen et al., 1990, Clemmons et al., 1990). 
IGFBP-1 has been shown to inhibit IGF-dependent cellular growth and differentiation in 
vitro (Lee et al., 1997a) as well as in vivo (Gay et al., 1997; Schneider et al., 2000). 
 
2.8.13 Carbonic anhydrase 2 (CA 2) 
Carbonic anhydrases are enzymes that catalyze the hydration of CO2 to produce HCO3- 
and H+. The predominant cytoplasmic isozyme is carbonic anhydrase 2 (Sly, 1995). CA 2 
plays an important role in the osteoclast differentiation, and bone resorption (Lehenkari et 
al, 1998). CA 2 deficiency is associated with osteopetrosis, renal tubular acidosis, and 
cerebral calcification (Sly and Hu, 1985). 
 
2.8.14 Major acut phase protein (MAP)  
Major acut phase proteins are glycoproteins produced in mammalian liver in response to 
tissue injury and inflammation (Anderson et al., 1984). MAP was shown to be identical to T-
kininogen, which is a cysteine proteinase inhibitor (Coleet al., 1985; Kitamura et al., 1987). 
MAP expression is induced by interleukin-6 in the liver during acute phase response. 
Krattenmacher et al., (Krattenmacher et al., 1994) have previously reported oestrogen-
regulation of other acute phase proteins. 
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2.8.15 Apolipoprotein A I (ApoA-I) 
Apolipoprotein A-I, the major protein component of HDL, is synthesized by the liver and 
intestine (Lamon-Fava et al., 1999). ApoA-I plays an important role in the protection 
against arteriosclerotic vascular disease, because it provides shuttle mechanism that 
transports excess esterified cholesterol from extrahepatic tissues back to liver for excression 
to bile salts (Franceschini et al., 1991). E2 treatment is known to increase ApoA-I protein 
level in plasma (Kalin and Zumoff, 1990) and ApoA-I gene in liver cells (Lamon-Fava and 
Micherone, 2004). 
 
2.8.16 Hepatic nuclear factor 3 γ (HNF-3γ) 
Hepatocyte nuclear factor-3 is a member of the large family of forkhead transcription 
factors that are distinguished by the presence of a winged-helix motif transcription factor 
(Lai et al., 1993). Three distinct members of HNF-3 (HNF-3α, -3β and -3γ) have been 
identified so far (Kaestner et al., 1994). Numerous reports have shown that each member 
plays distinct roles in differentiation, inflammation, cell growth and gene regulation (Lai et 
al., 1993). HNF-3γ is involved in the regulation of liver-specific and other genes in 
metabolic tissue (Allander et al., 1997; Roux et al., 1995). 
 
2.8.17 Angiotensin converting enzyme (ACE) 
Angiotensin converting enzyme is a zinc-containing dipeptidyl carboxypeptidase that plays 
an important role in the regulation of cardiac function and blood pressure (Welches et al., 
1993, Villard and Sourbrier, 1996). This enzyme is responsible for the local conversion of 
angiotensin I to the potent vasoconstrictor angiotensin II (Ferrario and Flack, 1996). 
Oestrogen may mediate a cadioprotective effect by decreasing the ACE expression and 
thereby its activity (Gallagher et al., 1999).  
 
2.8.18 Nitric oxide synthase 3 (NOS 3) 
The nitric oxide synthase has been shown to play an important role in the physiological 
regulation of local blood flow and blood pressure (Forstermann et al., 1998; Jonsdottir et 
al., 1998). Three isoforms of NOS have been identified, NOS 1, NOS 2 and NOS 3, which 
are regulated by Ca2+ and calmodulin (Wang and Marsden, 1995). 17-β-oestradiol, one of 
the few physiological regulators of endothelial NOS 3 (Harrison et al., 1995), significantly 
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enhances endothelial NO production in animal and man, contributing to its cardiovascular 
protective action (Kauser et al., 1997). 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Solutions and buffers  
All solutions and buffers used in this work were prepared with double distilled water (dd 
water). For RNA extraction and the PCR reactions, DEPC-treated water and HPLC water 
were used respectively. 
DEPC treated water 0.5 ml diethylpyrocarbonate (DEPC) was mixed 
with 500 ml dd water in an RNAse-free glass 
bottle and let stand overnight. The next day the 
DPEC treated water was autoclaved for 20 min at 
121 °C. 
 
DMEM/F12 (5l) 78.5 g of DULBECCO’s modified eagle medium 
powder with 1.0 g/l D-glucose without phenol-red, 
50 ml of Penicillin/Streptomycin (1000 
U/1000µg/ml), 12.2 g of NaHCO3 (30mM) were 
mixed with 4.95 l of dd water. pH adjusted to 7.4 
and solution filtered through a 0.22 µm pore filter. 
 
Reaction buffer for AlkP activity  5 g Mannitol; 2.21 g CAPS and 200 µl 2M MgCl2 
were mixed in 100 double distilled water (dd 
water) and the pH was adjusted to 10.4 with 
NaOH. 
 
Nitrophenylphosphate solution  
(4 mM) 
14.8 mg Nitrophenylphosphate were dissolved in 
10 ml reaction buffer. This solution corresponded 
to a final concentration of Nitrophenylphosphate 
of 4 mM. 
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Table 1: Chemical composition of buffer used for cell washing (PBS). The components 
were dissolved in 5 l dd water and adjusted to pH 7.4. 
 
 Salt Amount in mass 
 NaCl 40 g 
 KCl 1 g 
 Na2HPO4 x 2 H2O 7.2 g 
 KH2PO4 1.2 g 
Buffers for gel electrophoresis  
 
50x TAE-buffer  242 g Tris base, 57.1 ml acetic acid, and 100 ml EDTA (0.5 M) 
volume adjusted to 1 l with dd water and to pH 8.3 with NaOH. 
 
6x Loading buffer 40% Sucrose, Bromophenol blue (1 “pinch”), 1 ml EDTA (0.5 M) and 
Xylencyanol (1 “pinch”). Volume adjusted to 10 ml with dd water 
Buffers for SDS-PAGE and Western Blot: 
 
1x Lysis buffer (protein-buffer) 15.0 ml SDS (10%), 6.3 ml 4x stacking gel buffer, 5.0 
ml glycerine were mixed with 73.8 ml dd water. 
Tablets of a protease inhibitor cocktail (final 
concentration 1 mM), were added to lysis buffer just 
before use 
 
1x Coomassie reagent 2.5 g brilliant blue G250, 0.1 l acetic acid, 0.45 l 
methanol were mixed with 0.45 l dd water. 
  
Decolourisation solution 0.1 l acetic acid, 0.3 l methanol were mixed with 0.6 l 
dd water. 
  
Loading buffer 2.5 ml 4x stacking gel buffer 
6.0 ml 10% SDS 
2.0 ml glycerine 
8.4 ml dd water and  
1.0 ml bromophenol blue (1%) 
 
SDS solution (10%): 100.0 g SDS (0.35 M) were mixed with 1 l of dd-
water 
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4x Resolving buffer 90.8 Tris (1.4 M), 2.0g SDS (13.9 mM) were 
dissolved in dd water. Then the pH was adjusted to 
8.8 with HCl and the volume completed to 0.5 l with 
dd water. 
 
4x Stacking buffer 30.3 g Tris (0.35 M), 2.0 g SDS (13.9 M) were 
dissolved in 0.5 l dd water and the pH adjusted to 6.8 
with HCl. 
 
10x Running buffer 30 mg Tris (0.23 M), 144 mg glycine (1.9 M) in 1 l 
dd water. 
 
Table 2: preparation of PAGE gels 
 
Solution Resolving gel (10%) Stacking Gel (4.5%) 
Acrylamid/bisacrylamid 30% 11.65 ml 1.5 ml 
Aqua. Bidest. 14.04 ml 5.8 ml 
4x Resolving buffer 8.5 ml - 
4x Stacking buffer - 2.5 ml 
Ammoniumpesulfat (APS) 4% 0.55 ml 0.2 ml 
TMED 30 µl 30 µl 
 
Buffers for the transfer and the immunodetection of proteins 
 
1x Running buffer 0.1 l 10x running buffer, 10 ml SDS (10% w/v) 
were mixed in 1 l dd water 
  
Blocking buffer (150 ml) 15 ml 10x TBS, 7.5 g nonfat dry milk, 135 ml dd 
water were mixed. When stirring, 0.1 ml 
Tween 20 was added. 
  
Primary antibody dilution buffer 2 ml 10x TBS added to 18 ml dd water and 
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mixed. 1 g BSA added and mixed well; while 
stirring 20 µl Tween 20 added. 
  
1xTransfer buffer 100 ml 10x running buffer, 10 ml SDS (10 %), 
100 ml methanol volume adjusted to 1 l with 
dd water 
Coomassie solution 0.45 l dd water, 0.45 l methanol, 0.1 l acetic acid 
and 2.5 g brilliant blue G250 
  
10x TBS (Tris-buffered saline)  24.2 g Tris, 80 g NaCl adjusted to 1 l with dd 
water and pH 7.6 with HCl 
  
Washing buffer 20 ml NaCl (5 M), 10 ml Tris (1 M), 1 ml Tween 
20 (% v/v) were mixed in a final volume of 1 l 
dd water 
  
Stripping buffer Tris (62.5 mM), SDS (2%) mixed in with dd 
water (final volume 1 l). Mercaptoethanol 
(final concentration 100 mM) added few min 
prior to use. 
 
3.1.2 Culture media for yeast 
The yeast, Saccharomyces cerevisiae, was grown in a minimal medium containing several 
additional components. The media and solutions were prepared with dd water, sterile-filtered 
through 0.2 µm pore size filters and stored at 4-5°C in sterile glass bottles. The actual 
composition of the media and the solution are presented in table 3. 
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Table 3: The basic chemical composition of the medium for yeast culture 
 
 Chemical content 
Minimal Medium (pH 7.1) 13.61 g KH2PO4; 1.98 g (NH4)SO4; 4.2 g KOH pellets; 0.2 
g MgSO4; 1 ml Fe2(SO4)3 solution (40 mg/50 ml H2O); 50 
mg L-leucine; 50 mg L-histidine; 50 mg adenine; 20 mg L-
arginine-HCl; 20 mg L-methionine; 30 mg L-tyrosin; 30 
mg L-isoleucine; 30 mg L-lysine-HCl; 25 mg L-
phenylalanine; 100 mg L-glutamic acid; 150 mg L-valine; 
375 mg L-serine; 1 l dd water 
Vitamin solution 8 mg thiamine, 8 mg pyridoxine, 8 mg pantothenic acid, 40 
mg inositol, and 20 ml biotin solution (2 mg/100 ml H2O) 
to 180 ml dd water. 
 
3.1.3 Test organisms 
3.1.3.1 Yeast strain  
The yeast strain of Saccharomyces cerevisiae was used for early investigation for oestrogenic 
properties of potential phytoestrogen in this work: The strain of Saccharomyces cerevisiae 
was genetically modified to contain the DNA sequence of the human oestrogen receptor 
together with the expression plasmids carrying the oestrogen-responsive elements (ERE) 
controlling the expression of the reporter gene lac-Z (encoding the enzyme β-galactosidase). 
This modified yeast strain was developed and supplied by Professors Sohoni and Sumpter, 
Brunel University, UK (1998). 
3.1.3.2 Cell lines (Human cells) 
Three human cell lines were used as model system in this work. All cells used in the 
investigation were kept in liquid nitrogen. The details of the cell lines used in the 
investigations were as follows: 
MCF-7 cells: The oestrogen-responsive human breast adenocarcinoma cell line, MCF-7 was 
purchased from the German National Resource Centre for Biological Material 
(DSMZ).  
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MVLN cells: MVLN cells were obtained from Doctor M. Pons, Institut National de la Santé 
et de la Recherche (INSERM, Montpellier, France). This cell line is based on 
human MCF-7 cells containing an oestrogen-regulated luciferase reporter gene 
driven by an oestrogen-responsive element (ERE) of the vitellogenin A2 gene 
fused to the thymidin-kinase-promoter (Pons et al., 1992). Therefore, the specific 
transcription activity of a test chemical is directly related to the activity of 
luciferase measured. 
Ishikawa cells: The Ishikawa cell line chosen as a model for endometrial epithelial cells is 
derived from a well-differentiated endometrial adenocarcinoma. This cell 
line was obtained from Professor Masato Nishida (Kasumigura, National 
Hospital, Ibaraki-ken, Japan) 
3.1.3.3 Animals 
Female Wistar rats (weight about 150 g) were obtained from Charles River (Charles River 
Wiga GmbH, Sulzfeld, Germany). The animals were housed in plastic cages in an 
environmentally controlled room (temperature 20°C; humidity 50-80%; 12-hour light/dark 
cycle). They were provided with tap water ad libitum and a standard rat diet (SSniff R10-
Diet, SSniff GmbH, Soest, Germany). All animal husbandry handling conditions were 
according to the Institutional Animal Care and Use Committee guidelines, regulated by the 
German Federal law for animal welfare. 
 
3.1.4 Substances 
 
17β-oestradiol  Purchased from Sigma (Taufkirchen, Germany) 
Fulvestrant Purchased fromTocris (Bristo, UK) or kindling 
provided by Schering AG (Berlin, Germany) 
 
3.1.5 Test chemicals – plant extracts 
Figure 10 shows the structures of the six isoflavones used in this work. The collection of the 
plant Millettia griffoniana, the extraction, the isolation, and the purification of test substances, 
4’-O-geranylisoliquiritigenin (4-O-GIQ), 7-O-geranylformononetin (7-O-GF), Griffonianone 
E (Griff E), Griffonianone C (Griff C), 3’,4’-dihydroxy-7-O-[(E)-3,7-dimethyl-2,6-
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octadienyl]isoflavone (7-O-GISO) and 4’-methoxy-7-O-[(E)-3-methyl-7hydroxymethyl-2,6-
octadienyl]isoflavone (7-O-DHF) were described previously by Yankep et al (Yankep, 1998; 
Yankep, 2001). The analysis of the NMR-proton spectrum and the mass-spectrum of the six 
compounds studied in this work clearly showed that all of them were obtained as crystal. 
Substances from Milletia griffoniana were dissolved in DMSO and then stored in stock 
solutions of 10-7; 10-6; 10-5 10-4; 10-3 and 10-2 M at room temperature. 
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3.2 Methods 
3.2.1 Preparation of DCC-FCS solution 
To eliminate oestrogens contained in the serum, fœtal calf serum (FCS) was treated by 
mixing two pieces of the dextran-coated active charcoal (DCC) pellets with 0.5 l FCS. The 
mixture was incubated for 2 h at 4°C, filtered successively using 100 µm and 90 µm pore size 
filters with a final 0.2 µm filter. The FCS and the DCC-treated FCS were stored at -20 °C. 
For the MCF-7 and MVLN cells culture 500 ml basal medium was supplemented with 1.65 
ml of Gentamycin (10 mg/ml), 10 ml of Sodium pyruvate (100 mM) and the desired 
amounts of either FCS or DCC- treated FCS 
 
3.2.2 Cell culture of MCF-7, MVLN and Ishikawa cells  
For the human cell culture, Dulbecco's Modified Eagle's Medium/ F12 (DMEM/F-12) was 
used. The cell culture was done under sterilised conditions using a laminar flow hood. 
MVLN and MCF-7 were routinely cultured in 75 cm2 plastic culture flasks containing 
15 ml DMEM/F12 supplemented with 10 % fetal calf serum (FCS), gentamycin 
(10 mg/ml), at 37 °C in a incubator with 5% CO2 and a humidified atmosphere. Ishikawa 
cells were maintained in DMEM/F12 supplemented with 5% DCC-FCS and insulin-
transferin-selenium-A. After 2-3 days, confluent monolayer cells were sub cultured until 
they were used for experiments. 
3.2.3 Yeast recombinant assay 
3.2.3.1 Preparation of Growth medium 
Yeast growth medium was prepared by mixing 5 ml glucose solution (20% w/v in dd water), 
1.25 ml of L-aspartic acid solution (4 mg/ml in dd water), 0.5 ml of vitamin solution, 0.4 ml 
of L-threonine solution (24mg/ml in dd water), and 125 µl of copper (II) sulphate solution (20 
M) to 45 ml Minimal Medium in a sterile conical flask.  
3.2.3.2 Assay procedure- Incubation with tests substances  
Frozen yeast culture (-20°C) was incubated at 28-32 °C for 24 hours to attain an optical 
density of 1.0 at 590 nm. Fresh growth medium mixed with defined yeast suspension (1.0 
OD590) was mixed with chromogenic substrate (CPRG) for the assay. Serially diluted test 
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substances in DMSO were loaded into the well of a clear 96-well polystyrene flat-bottomed 
microtitre plate. DMSO in each well had not exceeded 1 %. 200 µl/well aliquots of the assay 
medium were then added using a multi-channel pipetter. Plates were then sealed with a 
parafilm foil along the edge to minimize evaporation and incubated at 32 °C for 2-3 days on 
an orbital shaker (70 rpm) to enable the oestrogen-induced synthesis β-galactosidase and the 
conversion of the substrate by induced β-galactosidase, resulting in a colour development 
from yellow to red, indicating the presence of oestrogenic activity. 
Samples were tested in quadruplicate, and a standard curve for E2 (10-12-10-8 M) used as 
positive control was included in each assay. The concentration of the test substances ranged 
from 10-8 M to 5x10-6 M. 
After 2-3 days incubation, the plates were removed from the incubator and the colour 
change of the medium was check at an absorbance of 565 nm and 590 nm. 
3.2.4 Luciferase reporter gene assay 
3.2.4.1 Assay procedure 
MVLN cells were plated at 2.5x105 cells/well in into 6-well plates in DMEM/F12 
containing 5% DCC-FCS and allowed to grow for 2-3 days to reach 70-80% confluence. 24 
hours prior to the treatment the serum supplementation of the medium was reduced to 1% 
DCC–FCS. The next day cells were treated with the test compounds (10-10-10-5 M), or 
oestradiol (10-8 M, positive control), and vehicle (DMSO, negative control) and incubated 
at 37°C in a 5% CO2 atmosphere. The luciferase activity was determined after 24 h using 
the Luc assay system as recommended from Promega. 
3.2.4.2 Luciferase activity 
To extract luciferase, 200 µl of one-fold (1x) lysis buffer (Promega) was added to each well. 
Cells were then detached with a scraper, transferred to a 1.5 ml reaction tube, vortexed for 15 
s and centrifuged for 1 minute at 12,000 g to clarify the extract.  
Duplicate aliquots of the cell lysate (samples) (10 µl) were loaded into a white 96-well 
microtiter plate. Then, 50 µl of the Luciferase Assay Reagent (Promega E1501) were added 
to each well and the product of the reportergene, the luciferase enzyme contained in the cell 
lysate, catalysed the mono-oxygenation of the substrate, D-luciferin with light emission at a 
specific wave length. The luminescence induced by the conversion of the substrate was 
measured at room temperature using a Genios microplate reader (Tecan).  
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To compare data, the protein content of each extract was measured using the bicinchoninic 
acid (BCA) method, with bovine saline albumin (BSA) as protein standard. Luciferase 
activity was calculated in relative light units (RLU) per mg of protein. 
This experiment was performed at least three times, with duplicate for each treatment. 
3.2.5 Alkaline phosphatase assay with Ishikawa cells 
Ishikawa cells were seeded in 12-well plates at a density of 1.25 x105 cells per well in 500 
µl medium. Tests compounds, dissolved in DMSO were added, the concentrations ranging 
from 10-10 M to 10-5 M. E2 (10-7) was used as positive control and DMSO as vehicle 
control. Treated cells were afterwards incubated for 72 h at 37 °C. After incubation, cells 
were trypsinised and ice-cold reaction buffer was added. The tubes were placed on ice and 
cells were sonicated for 10 s at 50% and ½ impuls using an ultra-sound disintegrator. 
Alkaline phosphate activity was assayed by a colorimetric method based on the conversion 
of the substrate, p-nitrophenylphosphate to p-nitrophenol as described previously (Holinka 
et al., 1986). The kinetic of the product formation was read at 405 nm. The ∆E/min values 
were converted to mU/ml. The alkaline phosphatase activity was normalised to the total 
quantity of protein for each cell homogenate and expressed in mU/mg protein. This AlkP 
activity was determined in triplicate for each sample. 
 
3.2.6 Gene expression  
3.2.6.1 Primer design 
The query of the oligo-nucleotides used in this work as PCR-primers was done using the 
BLAST programs of the NCBI (National Centre for Biotechnology Information, 
http://www.ncbi.nlm.nih.gov/) and the program Primer 3. PCR-primers were chosen based on 
the following criteria:  
• the melting temperature of the primers should be about 50 °C  
• the difference between the melting temperature of the forward and the reverse should 
not exceed 5 °C,  
• the proportion of the G/C in each primer has to be 40-60%.  
The oligo-nucleotides (primers) had a length of 20-23 base pairs. 
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3.2.6.2 Primer optimization and efficiency measurement 
To determine the quantity of primers necessary for running optimized-PCR reactions, the 
efficiency (E) of each primer was evaluated. Firstly, PCR-Mix was made with components 
maintained constant excepted the primers which amount varied: 0.5; 1; 1.5; and 2 µl (forward 
and reverse). Secondly, Real-time PCRs were run and the optimal quantity of primers 
determined. In order to obtain accurate and reproducible results, primer efficiency was 
determined by generating a serial of four tenfold dilution of target gene cDNA template. After 
performing real-time PCR, the Ct value for each dilution was determined and a plot of the CT 
versus log of cDNA concentration was constructed. Amplification efficiency was then 
calculated from the slope of this graph using the equation: 
E= [10-1/slope]-1 
With this method, the expected slope of a 10-fold dilution serie is 3.32 when efficiency 
equal to 1.0. Indeed, the efficiency of the target amplification and the efficiency of the 
endogenous control must be approximately close and both efficiencies have to be close as to 
100% as possible. 
3.2.6.3 Treatment of MCF-7 cells for gene expression analysis 
MCF-7 cells in DMEM/F12 medium without phenol red and supplemented with 5% DCC-
FCS were plated into 6 well plates (6x 105 per well) and allowed to attach for 24 hours before 
the treatment. The medium was changed against DMEM/F12 with 1% DCC-FCS, and cells 
were treated with Griff C at concentrations ranging from 10-10 to 10-6 M. After 24 hours, RNA 
extraction was performed. 
3.2.7 Uterotrophic bioassay  
A standard rodent uterotrophic assay was used to assess the in vivo oestrogenic effects of 
Griff C (2, 10, and 20 mg/kg body weight) and compare to E2 (positive control 10 µg/kg 
body weight), and castor oil (vehicle control). The substances were dissolved each in 500 µl 
ethanol and solutions were mixed with 4.5 ml castor oil to obtain the desired concentration. 
Female rats were successively anaesthetised by intra muscular injection of a combination of 
ketamine and xylazine (100 mg/kg BW and 10 mg/kg BW respectively) and 
ovariectomised. 14 days after ovariectomy, rats were given daily (at the same time) 
subcutaneous injections of vehicle (control, OVX), Griff C, or E2 for three consecutive 
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days and after sacrificing them uteri, livers and fragments of vena cava were removed for 
gene expression analysis. All collected tissues were immediately stored in liquid nitrogen. 
Animals were randomly divided into five groups of six rats each. 
The outline of the treatment is summarised in the following table. 
 
Table 4: outline of the treatment 
 
Group Animals/group Final concentration of substance 
OVX 6 500 µl Ethanol in 5 ml castor oil 
E2 10  6 E2 (10 µg/kg/BW)  
Griff C 2 6 Griff C (2 mg/kg/BW)  
Griff C 10 6 Griff C (10 mg/kg/BW)  
Griff C 20 6 Griff C (20 mg/kg/BW)  
 
3.2.8 Total mRNA extraction from cells and tissues 
Adherent cells like MCF-7 and Ishikawa cells were lysed directly in Trizol® reagent 
according to the manufacturer’s advice. For the total mRNA preparation from cryo-conserved 
tissues, 80 to 100 mg were dismembrated using a tissue-dismembrator. The tissue powder 
was then homogenized in Trizol® solution and processed according to the manufacturer’s 
instructions. RNA concentration was measured at 260 nm and 280 nm and calculated using 
the following formula:  
O.D260. x dilution factor x 40 µg/ml (conversion factor for RNA) = [RNA µg/ml]. 1OD260 nm 
corresponds to 40 µg/ml RNA for a layer of 1 cm thickness. 
The ratio between [260nm] and [280nm] was calculated to determine the purity of the RNA 
solution. Pure RNA should give a value of 2.0  
The quality of the RNA was checked by 1% agarose gel electrophoresis. The RNA sample 
was considered as good quality when the staining of the 28S band was twice as intense as the 
18S band. The quality of the rRNA was then used as an indication of the quality of mRNA. 
3.2.9 DNAse digestion of genomic DNA  
To remove any DNA contamination in RNA preparation 3 µg RNA of each sample was 
mixed in 0.2 ml thin-walled PCR-tubes with 1 µl PCR buffer, 0.5 µl RNAse inhibitor 
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(40 U/µl); and 0.5 µl of DNAse (1 U/µl) and the volume adjusted to 10 µl. This mix was 
incubated for 30 min at 37 °C in a PCR thermal cycler with a heated lid. 
To inactivate the DNAse and to bind free Mg2+, 1 µl EDTA (25 mM) was added to each 
PCR tube, which was afterwards incubated for 5 min at 80 °C. Equal amounts of total RNA 
from six rats in the same experimental group were pooled before cDNA synthesis. To verify 
whether the genomic DNAse digestion was complete, real-time PCR was performed. 
3.2.10 Complementary DNA (cDNA) synthesis  
The synthesis of the single stand DNA (cDNA) complementary to the mRNA was done using 
two different protocols.  
3.2.10.1 Method of Sambrook and Manniatis  
Reverse transcription was performed using the protocol of Sambrook (Sambrook and 
Manniatis, 1989). The reaction was carried out in a 20 µl (total volume) mixture containing 3 
µg RNA, 2 µl Manniatis buffer, 2 µl dNTP-mix, 1 µl oligo (dT)12-18 (100 µg/ml), 0.5 µl 
RNAse inhibitor (20 U) 1 µl MgCl2 (50 mM), and 1µl AMV reverse transcriptase (100-200 
U). 
The reaction was run in a cycler for 30 min at 37 °C. After this incubation, the inactivation of 
the reverse transcriptase enzyme was done by increasing the incubation temperature to 95 °C 
for 5 min. 
The cDNA samples were store at -20°C until used for PCR reactions. 
3.2.10.2 Invitrogen Protocol using Superscript II  
For the first-strand cDNA synthesis, 3 µg of RNA in total volume of 10 µl HPLC-treated 
water, together with 1 µl oligo (dT)12-18 (500 µg/ml) and 1 µl dNTPs were incubated at 65°C 
for 5 min to denature the secondary structure of mRNA and cooled on ice. 4 µl 5x first strand 
buffer, 2 µl dithiothreitol (0.1 M) and 1 µl RNAse inhibitor (40 U/µl) were added, slightly 
mixed, and incubated for 2 min at 42°C, allowing primers to hybridize at the poly(A) tail of 
the mRNA. For the reverse transcription itself, 1 µl SuperScript® II reverse transcriptase (200 
U) was added. The reaction was allowed to proceed for 60 min at 42°C after which the 
enzyme was inactivated at 70°C for 15 min. 
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3.2.11 Real-time PCR 
Real-time PCR is a highly sensitive method used in the analysis of gene expression. The 
polymerase chain reaction allows the in vitro logarithmic amplification of a specific DNA 
fragment using a DNA polymerase enzyme. SYBR green I, a dye that binds to double 
stranded DNAs but not to single-stranded DNAs, was used to monitor the synthesis of DNA 
online during real-time PCR reactions. The table 5 shows the master mix used for the PCR 
reactions. 
Table 5: Reaction setup for one real-time PCR. 
 
Component Volume /reaction Final concentration 
HPLC-treated water Variable (µl)  
2xSybrGreen I in 10xPCR buffer 5µl 0.2x 
MgCl2 (50 mM) Variable (2-4 µl) 2-4 mM 
dNTP-Mix (2.5 mM each) Variable (2 or 4 µl) 0.2 mM or 0.4 mM 
Fluorescein calibration dye (400nM) 1.25µl 10 mM 
Platinum Taq DNA polymerase (5 U/µl) 0.1µl 0.5 U/ reaction 
Primers (10mM each) Variable (0.5-4 µl) 0.1-0.4 mM 
Template cDNA 1µl ng/reaction 
Total volume 50µl  
 
Reactions were carried out for 50 cycles (denaturation 95°C for 10 sec, annealing at 60°C for 
15 sec, and elongation at 72°C for 30 sec following an initial incubation for 3 min at 95°C). 
The reactions were run in triplicate. Table 6 summarises cycling conditions for real-time 
PCR. 
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Table 6: Cycling conditions for real-time-PCR 
 
Step Time for 
each cycle 
Temperature cycle 
Number
Additional 
comments 
PCR initial activation 
step 
3 min. 95°C 1 The DNA polymerase is 
activated by this heating 
step 
Denaturation 10 s 95°C  
Annealing 15 s 60°C  
Extension (or 
elongation) 
30 s 72°C 
50 
Fluorescence data 
collection 
Melting curve 
analysis 
7 s  60-95°C 70  
 
During PCR reactions, the accumulation of amplicons was detected and data were 
continuously computerised by the program iCycler IQ optical system software version 3.0a 
from Bio-rad. 
 
3.2.12 Analysis of real-time PCR results 
The relative mRNA amounts of target genes were calculated using the comparative cycle 
threshold method (∆∆CT method) (Winer et al., 1999) with the mitochondrial cytochrom C 
oxidase subunit 1A (1A) as endogenous reference gene, and relative to the vehicle control. 
The particularity of the reference gene i used in my study is that, it has a higher expression 
level than the targets genes and its expression is not affected by the treatment. The 
calculations for the PCR quantification starts with getting the difference (∆CT) between the 
CT values of the target and the reference gene: ∆CT = CT (target) - CT (reference) 
This value was calculated for each sample to be quantitated. The samples from vehicle-treated 
animals or cells were chosen as the reference (baseline) for each comparison to be made. The 
comparative ∆∆CT calculation consisted of finding the difference between each sample’s 
∆CT and the baseline’s ∆CT. The last step in the quantification was to transform these values 
to absolute values. Therefore, the amount of target normalised to an endogenous reference 
and relative to a calibrator, is given by the following equation, assuming that reference and 
target genes have similar efficiencies close to 1: 
Comparative expression level = 2 – ∆∆CT = 2∆CTTarget –∆CTReference  
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Where: 
∆CTTarget = CT control (Target) - CTprobe (Target) and  
∆CTreference = CT control (Reference) - CTprobe (Reference) 
CT values higher than 35 were not included in the results because they approach the 
sensitivity limits of the real-time PCR detection system used. 
3.2.13 Effects of Griffonianone C and 17β-oestradiol on Protein kinase B (Akt) 
expression in MCF-7 cells 
3.2.13.1 Assay procedure 
One day prior to the experimentation trial, MCF-7 cells were incubated with 5 ml of 
DMEM/F12 containing 1% DCC-FCS. Cells were then treated with griffonianone C; estren, 
or genistein at the concentrations 10-10 M, 10-9 M, 10-8 M, 10-7 M and 10-5 M, and incubated 
at 37°C for 15 min. DMSO was used as vehicle control and E2 at the concentration 10-8 M as 
the positive control. Four separate trials were conducted. 
3.2.13.2 Cell lysate and preparation of protein samples 
Cells were lysed with ice-cold lysis buffer on ice. Lysate became quite viscous and the 
chromosomal DNA was sheared by passing the lysate repeatedly through a tip. The lysate 
was then centrifuged for 15 min at 14 000 g. This pelleted the cellular debris and the 
supernatant containing proteins was transferred to fresh microfuge tubes on ice. Aliquots for 
protein concentration determination were removed and the rest stored at -20 °C. After the 
protein assay, each sample was diluted to reach the concentration 1 µg/µl.  
An aliquot of 75 µl of each sample was mixed with 25 µl loading buffer and 10 µl DTT in 1.5 
ml reaction tubes and then heated for 5 min at 98 °C to denature proteins. Samples ready for 
electrophoresis were either kept on ice or stored at -20 °C. 
 
3.2.14 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
3.2.14.1 Electrophoresis 
Gelectrophoresis of 30 µl of each sample was run for about 1.5 h at a constant tension of 100 
V until the bromophenol blue front line reached the bottom of the gel. A prestained protein 
marker was used to allow detecting the molecular weight of the target protein. The 
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fractionated proteins were afterwards stained with coomasie blue or transferred to a 
nitrocellulose membrane for immunodetection purpose. 
The transfer of the proteins was performed as semi-dry blotting at room temperature for 2 at 
140 mA. To check the transfer of protein and to assess proteins loading, the membrane was 
stained with ponceau S. Coomassie blue staining was used to check the transfer efficiency. 
3.2.14.2 Immunoblotting 
The western blotting is a technique, which allows the detection of protein expression in cell or 
tissue utilising antibody/antigen interactions. Before the immunological detection, the 
membrane was incubated at room temperature in 20 ml blocking solution to block non-
specific binding sites of the antibodies on a rocker. The membrane was then washed three 
times for 10 min with the washing buffer. During the washings step, the primary antibody 
(anti-phospho-Akt) was diluted (1:1000 dilution factor) in the TBS-Tween 20. After washing, 
the membrane was incubated for 2 h at room temperature in 20 ml buffer containing anti-
phospho-Akt primary antibodies. Then the membrane was washed three times for 10 min. and 
then incubated with the goat anti-rabbit IgG horseradish peroxidase (HRP)-conjugated 
secondary antibody diluted in TBS-Tween 20 buffer (1:8000) for 2 h at room temperature 
with agitation. After incubation, the membrane was washed as described above. 
3.2.14.3 Detection of protein kinase B (Akt) 
For the detection of the HRP-labelled secondary antibody the ECL plus kit was used 
according to the manufacturer’s recommendations. The reaction was exposed to X-ray film. 
In parallel, the membrane was scanned using a scanner. The fluorescence of the protein bands 
was excited by a blue beam of wave length of 420 nm. The emitted light of 460 nm was 
detected by the scanner. 
3.2.14.4 Membrane stripping and re-probing 
After the first detection, the membrane was washed with the washing buffer, stripped and 
proceeded through a second detection using this time anti-Akt as primary antibody. 
Afterwards the membrane was re-blocked and re-probed like described under 3.2.14.3 
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3.2.15 Statistical analysis 
In this work, the significance of the difference between control and treated groups was 
determined using the analysis of variance (ANOVA) followed by Dunnett’s post hoc 
comparison. The statistical program used is XLSTAT-Pro (version 7.1, Addinsoft). The 
significance was determined at p-values <0.05, <0.005, or <0.001. For the fulvestrant 
antagonism in MVLN and Ishikawa cells, data were compared using t-test; a p-value less 
than 0.05 was considered significant. Results are expressed as mean ± standard deviation. 
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4 Results 
4.1 Response of the yeast screening to isoflavones from Millettia griffoniana 
The yeast recombinant assay was used to investigate the ability of six geranylated isoflavones 
from Millettia griffonianna to stimulate the synthesis of β-galactosidase in transformed yeast. 
The oestrogenic activities are shown in two panels (Fig. 11 a, b) for clarity reasons. 
At the concentration of 5x 10-6 M, 4’-O-geranylisoquiritigenin, 7-O-geranylformononetin, 
Griffonianone E (Griff E), Griffonianone C (Griff C), 3’,4’-dihydroxy-7-O-[(E)-3,7-dimethyl-
2,6-octadienyl] isoflavone (7-O-GISO), and 4’-methoxy-7-O-[(E)-3-methyl-7hydroxymethyl-
2,6-octadienyl] isoflavone (7-O-DHF) could achieve 59-121% of the gene induction obtained 
with 17β-oestradiol at the concentration of 10-8 M in the yeast system (Fig.11 a, b). At lower 
concentrations no induction of the synthesis of β-galactosidase was observed and moreover 
the dose-response pattern shows that the activity decreases at higher concentrations (10-6, 
5x10-6 M). All values are shown as percentage relative to the response of oestradiol at 10-8 M, 
which i set as 100%. Griff C and 4-O-GIQ were found to be the most potent substances. 
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Fig. 11 (a, b). Oestrogenic effects of test substances on the Lac-Z induction in human oestrogen 
receptor (hER) recombinant yeast. Data represent the mean ± SD of four independent 
experiments.  
 
Once the compounds from Millettia griffoniana have shown oestrogenic activities in 
oestrogen-inducible yeast receptor assay, they were next tested in a luciferase-reporter-gene 
assay. 
4.2 Effects of isoflavones from Millettia griffoniana on the luciferase expression 
All six isoflavones induced the luciferase activity in a dose-dependent manner (Fig. 12 a, b). 
However this induction was still moderate in comparison to 17β-oestradiol (10-8 M). At the 
concentration 10-6 M, all tested substances displayed an oestrogenic activity. The maximum 
luciferase activity was 122%; obtained with 7-O-DHF at the dose 10-6 M. Only Griff E and 7-
O-GISO exhibited oestrogenic activity at a concentration of 10-5 M. At lower doses none of 
these isoflavones showed oestrogenic activity. Responses of the cells to the treatment with 7-
O-DHF, 7-O-GF and 7-O-GISO were even more pronounced than that of the positive control; 
however they were active at high concentrations. 
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Fig. 12 (a, b). Effects of Isoflavones from Millettia griffoniana on luciferase induction. Results are 
expressed as percentage of the positive control oestradiol at the concentration 10-8 M set 
at 100%. Data represent the mean ± SD of three independent experiments. *p< 0.05, **p< 
0.005, ***p< 0.001 significantly different from the control group. 
 
As observed in the recombinant yeast screen, different potentials of phytoestrogens to 
stimulate the luciferase induction were measured in MVLN cells. The ranking was as follows: 
7-O-DHF > 7-O-GF > Griff C > Griff E > 7-O-GISO > 4-O-GIQ, as delineated from their 
activities at a concentration of 10-6 M.  
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4.3 Oestrogenic effects on the alkaline phosphatase activity in Ishikawa cells 
In the endometrial Ishikawa system, all test compounds (Fig 13 a, b) displayed a lower 
oestrogenic activity than oestradiol (10-7 M). For Griff E, and 7-O-GISO, the maximum 
alkaline phosphatase activity was found at the concentration of 10-5 M. The most effective 
concentration for 4-O-GIQ, 7-O-GF, Griff C, and 7-O-DHF was 10-6 M. Compared to the 
negative control (vehicle); the isoflavones induced 2-4.5 fold increases in alkaline 
phosphatase activity while oestradiol (10-7 M) exhibited a 5.9 fold increase. 
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Fig. 13 (a, b). Dose-response of phytochemicals on the alkaline phosphatase activity in Ishikawa 
cells. Data represent the mean ± SD of three independent experiments. **p< 0.005, ***p< 
0.001 significantly different from the control group.  
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4.4 Antagonisation by fulvestrant 
Fulvestrant (5 x10-10 M) was used to show that the effects of the test substances on oestrogen 
receptors specifically exert the increase in the luciferase activity by isoflavones from Millettia 
griffoniana. Co-treatment of MVLN cells with fulvestrant at a concentration of 5x10-7 M 
(Fig. 14) in combinational treatment with E2 or with isoflavones from Millettia griffoniana 
antagonised the oestradiol effect on luciferase activity by 55%.and the oestrogenic effect of 
test substances by 80%. For all test compounds, the fulvestrant treatment resulted in 
expression levels which were lower than the level of the negative control (DMSO). 
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Fig. 14. Relative induction of luciferase by simultaneous treatment with the pure antagonist 
fulvestrant (5x10-7 M), oestradiol (10-8 M) or test compounds at the concentration 10-6 M. 
§p< 0.05 (student’s t-test) 
 
Similarly, simultaneous treatment of Ishikawa cells with fulvestrant (5x10-7 M), and 
oestradiol (10-7 M) or test substances showed (Fig 15) a significant suppression of the alkaline 
phosphatase induction; however, this concentration of fulvestrant did not completely reduce 
the stimulation due to E2 (10-7 M) to basal level. 
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Fig. 15. Relative induction of luciferase by simultaneous treatment with fulvestrant (5x10-7 M), 
oestradiol (10-7 M) or test compounds at the concentration of 10-6 M. §p< 0.05 (student’s 
t-test) 
 
4.5 Effects of Griff C on Ki-67, CD1 and PCNA mRNA expression in MCF-7 
breast cancer cells. 
In this part of my work, Ki-67, PCNA and CD1 were used as marker of cell proliferation  
4.5.1 Effect of Griff C on the mRNA expression of Ki-67, CD1 and PCNA in MCF-7 
cells  
As expected, the mRNA expression of Ki-67 and CD1 was up regulated by 17β-oestradiol at 
the concentration of 10-8 M. Griff C could also induce a significant up regulation of the 
mRNA expression of both Ki-67 and CD1 at concentrations of 10-8 M (for Ki-67) and  
10-7 M. 
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Fig. 16. Dose-response effects of Griff C on the mRNA expression of proliferation markers Ki-67, 
PCNA and CD1 in MCF-7 cells. 
 
PCNA mRNA expression was up regulated by both E2 and Griff C. However, the up-
regulation was not found to be statistically significant. 
4.6 Uterotrophic assay 
From the overall picture of results obtained from in vitro studies, i selected Griff C for further 
analysis of trophic effects on the uterus in vivo and the analysis of its effects on the regulation 
of selected oestrogen-responsive genes in uterus, liver and vena cava of ovariectomised rats.  
4.6.1 Uterus wet weight 
The uterine wet weights in ovariectomised (OVX) rats following the administration of 
different doses of Griff C are shown in table 7. Griff C injected at the highest dose (20 mg/kg 
BW) produced a trend towards an increase of uterine weight but without statistical 
significance, while in the E2-treated group (10 µg/kg BW/day) uterine weight increased 4.5-
fold compared to vehicle control.  
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Table 7: Uterine wet weight of Wistar ovariectomised rats after daily s.c. injection of 
carrier castor oil (OVX), oestradiol (E2) and Griffonianone C. Data represent means ± SD, 
* indicates a significant difference as compared to the vehicle-treated animals. ***p< 0.001. 
 
Substance n Dose Uterine wet weight (mg) 
Vehicle control (OVX) 6  161.67 ± 18.35 
17β-oestradiol 6 10 µg/kg BW 926.67 ± 121.44 *** 
Giffonianone C 6 2 mg/ kg BW 213.20 ± 24.52 
Giffonianone C 6 10 mg/ kg BW 224.00 ± 54.13 
Giffonianone C 6 20 mg/ kg BW 222.00 ± 44.38 
 
4.6.2 Gene expression in uterus 
The expression of a variety of genes in the uterus of ovariectomised rat in response to Griff C 
was investigated. 
4.6.2.1 Oestrogen Receptors α and β mRNA expression 
ERα and ERβ mRNA expressions were reduced in response to E2 (Fig. 17). In contrast, Griff 
C did not significantly affect the gene expression levels of ERα, but it showed a clear down-
regulation of ERβ gene at the dose 20 mg/kg BW and a slight up-regulation of the same gene 
at the doses 2 mg/kg BW and 10 mg/kg BW (Fig. 17). 
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Fig. 17. Oestrogen Receptors α and β mRNA expression in uterus of Wistar ovariectomised rats. 
Data represent means ± SD. * indicates a significant difference as compared to the 
vehicle-treated animals. *p< 0.05, ** p< 0.005, ***p< 0.001. 
 
**
***
  * 
**
  Results 
 
 59
4.6.2.2 Complement C3 and Calcium Binding Protein 9kD mRNA expression 
To further assess the oestrogenic effect of Griff C on the uterus, the gene expression levels of 
Complement C3 (C3) and Calbindin 9kD (CaBP 9kD) were examined. These genes were 
selected first because they all carry an oestrogen responsive element (ERE) in their 
promoters. Each gene showed a unique pattern of regulation. Griff C at the dose of 20 mg/kg 
BW induced a significant up-regulation of the C3 mRNA levels. The increase of this gene 
containing a triple ERE in its promoter was 49-fold compared to the negative control but still 
less than after treatment with E2 (Fig 18 a, b). 
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Fig. 18 (a, b). C3 mRNA expression in uterus of Wistar ovariectomised rats. Data represent means 
± SD. * indicates a significant difference as compared to the vehicle-treated animals **p< 
0.005, ***p< 0.001. Note that b) is identical to the part of a) representing Griff C only. 
Both Griff C and E2 up regulated the CaBP 9kD mRNA level in the uterus (Fig.19). E2 could 
increase the CaBP 9kD mRNA expression for about 40-fold in comparison to vehicle treated 
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rats, whereas Griff C had no effect at lower doses and its effect was almost half of that of E2 
at the dose of 20 mg/kg BW. 
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Fig. 19. Calcium Binding Protein 9kD mRNA expression in uterus of Wistar ovariectomised rats. 
Data represent means ± SD. *indicates a significant difference as compared to the vehicle-
treated animals. ***p< 0.001  
 
4.6.2.3 Vascular Endothelial Growth Factor and Progesterone Receptor mRNA 
expression 
The gene expression of VEGF was strongly reduced in the uterus of ovariectomised rats 
treated with oestradiol or Griff C. E2 reduced the VEGF mRNA expression by 68% and Griff 
C has clearly induced a dose-response down-regulation (Fig. 20) with a 53% reduction at 20 
mg/kg BW and 35% at 10 mg/kg BW. 
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Fig. 20. Progesterone Receptor and Vascular Endothelium Growth Factor mRNA expression in 
uterus of Wistar ovariectomised rats. Data represent means ± SD *indicates a significant 
difference as compared to the vehicle-treated animals. **p< 0.005, ***p< 0.001  
 
Figure 20 also shows a significant down-regulation of the PR mRNA expression induced by 
the treatment of OVX rats with both E2 and Griff C respectively. The percentages of 
reduction for the PR mRNA were 69% for E2 and 46 to 52% for Griff. C 
4.6.2.4 Clusterin and Cyclooxygenase 2 mRNA expression  
As an example of a gene containing no ERE the regulation of the Clusterin (CLU) gene 
expression was examined as a sensitive marker for oestrogenic action in the uterus. A strong 
decrease of the uterine CLU gene expression was found in E2-treated rats. A dose-dependent 
decrease of CLU and RNA was also observed in animals treated with Griff C (Fig. 21) as 
94% for E2 and 64% for Griff C at the dose 20 mg/kg BW.  
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Fig. 21. Clusterin and Cyclooxygenase 2 mRNA expression in uterus of Wistar ovariectomised rats. 
Data represent means ± SD *indicates a significant difference as compared to the vehicle-
treated animals. ** P< 0.005, ***P< 0.001  
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I further examined the expression of cyclooxygenase 2 (COX 2) (Fig 21) which was down-
regulated in the uterus of OVX rats by Griff C dose-dependently but less potent than by E2. 
4.6.2.5 Insulin-Like Growth Factor mRNA expression 
A slight up-regulation of IGF-1 expression was observed following treatment with Griff C 
2 mg/kg BW, whereas E2 and Griff C at the dose 10 mg/kg BW and 20 mg/kg BW reduced 
the IGF-1 mRNA by 58%, 40%, and 44% respectively. 
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Fig. 22. Insulin-like Growth Factor 1 mRNA expression in uterus of Wistar ovariectomised rats. 
Data represent means ± SD. * indicates a significant difference as compared to the 
vehicle-treated animals.*p<0.05 **p< 0.005  
 
4.7 Oestrogenic responses in other target organs 
The effects of oestradiol and Griff C of mRNA expression were not only assessed in the 
uterus, one of the major target organs of sex hormones, but also in the liver and vena cava. 
4.7.1 Gene expression in the liver of ovariectomised rats 
To study the effect of Griff C on the expression of selected oestrogen-induced genes in the 
liver, i analysed the expression of CLU, major acute phase protein (MAP), carbonic 
anhydrase 2 (CA2), insulin like growth factor 1 (IGF-1), and insulin like growth factor 
binding protein 1 (IGFBP-1) in the liver of ovariectomised rats treated with E2 or Griff C. 
** *
*
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4.7.1.1 Clusterin and Insulin-Like Growth Factor Binding Protein I mRNA expression  
As observed in the rat uterus, the expression of CLU in the liver was also down-regulated due 
to the exposure to E2 (60%) and Griff C (44%) (Fig. 23). In this study, IGFBP-1 was up-
regulated by E2, while Griff C at the dose 10 mg/Kg BW induced a significant down-
regulation of the expression of IGFBP-1 with almost 51% reduction (Fig. 23).  
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Fig. 23. Hepatic Clusterin and IGFBP-1 mRNA expression in Wistar ovariectomised rats. Data 
represent means ± SD. * indicates a significant difference as compared to the vehicle-
treated animals. ** P< 0.005, ***P< 0.001. 
 
4.7.1.2 Major Acute Phase Protein and Carbonic Anhydrase 2 mRNA expression 
For MAP and CA 2, an induction of mRNA levels could be detected (Fig. 24), however this 
up-regulation was only significant for CA 2. The highest stimulation by Griff C occurs at the 
dose of 10 mg/kg BW leading to a 2-fold increase of the MAP mRNA compared to vehicle 
treated rats. 
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Fig. 24. Hepatic Carbonic anhydrase and Major acute protein gene expression in Wistar 
ovariectomised rats. Data represent means ± SD. * indicates a significant difference as 
compared to the vehicle-treated animals. * p< 0.05. ** P< 0.005. 
4.7.1.3 Apolipoprotein A-I and Hepatic Nuclear Factor 3γ mRNA expression 
The expression of HFN-3γ mRNA was significantly reduced to less than 40% by E2 and 
Griff C at all three-tested doses (Fig. 25). ApoA-I mRNA expression was also down-
regulated by Griff C with the most pronounced effect at the highest dose. 
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Fig. 25. Hepatic Apolipoprotein A1 and Hepatic Nuclear Factor γ gene expression in Wistar 
ovariectomised rats. Data represent means ± SD. * indicates a significant difference as 
compared to the vehicle-treated animals. ** P< 0.005 *** P< 0.001.  
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4.7.2 Gene expression in vena cava of ovariectomised rats 
4.7.2.1 Oestrogen Receptor α and Progesterone Receptor mRNA expression 
As observed in uterus ERα mRNA expression in vena cava was reduced by E2, while Griff C 
showed no effect at the doses 2 mg/kg BW and 10 mg/kg BW. At the dose 20 mg/kg BW it 
increased ERα mRNA expression significantly. In contrast to the results obtained in uterine 
tissue, where PR mRNA expression was strongly reduced by both E2 and Griff C, PR mRNA 
expression is instead increased in vena cava in response both substances. Griff C exhibited a 
dose-dependent up-regulation of PR with a 2-fold increase in comparison to vehicle control 
(Fig. 26). 
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Fig. 26. ERα and PR mRNA expression in vena cava of Wistar ovariectomised rats Data represent 
means ± SD. *indicates a significant difference as compared to the vehicle-treated 
animals. *p< 0.05, *** p< 0.001. 
 
4.7.2.2 Vascular Endothelial Growth Factor (VEGF) and VEGF-Receptor-2 mRNA 
expression 
E2 had no detectable effect on the expression of both VEGF and VEGFR-2 compared to the 
vehicle control. In contrast, Griff C at the dose of 10 mg/kg/BW showed a significant mRNA 
up-regulation of VEGF and its receptor VEGFR-2, while the highest used dose of Griff C did 
not show any effect (Fig. 27). 
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Fig. 27. VEGF and VEGFR-2 mRNA expression in vena cava of Wistar ovariectomised rats. Data 
represent means ± SD. *indicates a significant difference as compared to the vehicle-
treated animals. *P< 0.05, ** P< 0.005. 
4.7.2.3 Angiotensin Converting Enzyme and Nitric Oxide Synthase 3 mRNA 
expression 
ACE mRNA expression in vena cava was increased in response to treatment with Griff C at 
the dose of 20 mg/kg BW and E2. At the other two tested doses of Griff C, no detectable 
regulation of ACE expression was observed (Fig. 28). NOS 3 mRNA expression was not 
affected by Griff C and E2 although there was a slight regression in the expression of NOS 3 
at the dose of 20 mg/kg BW. 
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Fig. 28. ACE and NOS3 mRNA expression in vena cava of Wistar ovariectomised rats. Data 
represent means ± SD. * indicates a significant difference as compared to the vehicle-
treated animals. *P< 0.05. 
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4.7.2.4 Proliferating Cell Nuclear Antigen and Ki-67 mRNA expression. 
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Fig. 29. PCNA and Ki-67 expression in vena cava of Wistar ovariectomised rats. Data represent 
means ± SD. * indicates a significant difference as compared to the vehicle-treated 
animals. ** P< 0.005. 
The level of PCNA and Ki-67 mRNA, both two represent proliferation marker, remained 
almost unaffected by the administration of E2 or Griff C except for the Ki-67 mRNA level 
which was up-regulated by Griff C (2 mg/kg BW and 10 mg/kg BW) (Fig. 29). 
4.7.2.5 Clusterin and Cyclooxygenase 2 mRNA expression  
Like in uterus, both Griff C and E2 down regulated the COX2 mRNA expression in vena 
cava compared to the vehicle treated group. For clusterin, mRNA expression was increased 
by E2 and remained unaffected by Griff C (Fig. 30). 
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Fig. 30. CLU and COX2 mRNA expression in vena cava of Wistar ovariectomised rats. Data 
represent means ± SD. * indicates a significant difference as compared to the vehicle-
treated animals. *P< 0.001. 
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4.8 Western blot analysis of the expression of Akt and phosphorylated Akt 
proteins in MCF-7 cells 
4.8.1 Effects of E2, and Griff C on the Akt activation 
Since Griff C did not significantly increase the expression of proliferation markers such as 
PCNA except CD1 and Ki-67, the investigation whether this substance could play a role in 
apoptosis (cell survival) by mediating the PI3K-Akt signalling pathway, was carried out.  
 
 
 
Fig. 31. Effect of 17β-oestradiol on Akt and phosphorylated Akt expression: Immunoblot of MCF-7 
treated by E2 for 15 min. Lane 1: 10-10 M E2; Lane 2: 10-9 M E2; Lane 3: 10-8 M E2; Lane 
4: 10-7 M E2; Lane 5: 10-6 M E2 
 
Human breast cancer cells MCF-7 in culture expressed Akt and phosphorylated Akt. Total 
Akt levels were nearly similar after 15 minutes treatment in all groups of cells. The 
expression of phosphorylated Akt at Ser473 was slightly down-regulated by oestradiol at 
higher concentrations (Fig. 31) and showed no effect at lower concentrations when 
compared to control cells. 
 
Fig. 32. Effect of Griff C on Akt and phosphorylated Akt expression: Immunoblot of MCF-7 treated 
by Griff C for 15 min. Lane 1: 10-10 M Griff C; Lane 2: 10-9 M Griff C; Lane 3: 10-8 M 
Griff C; Lane 4: 10-7 M Griff C; Lane 5: 10-6 M Griff C 
 
Griff C as shown in figure 32 increased the phosphorylation of Akt compared to the basal 
phospho-Akt observed in control cells.  
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4.8.2 Akt activation is affected by the PI3K inhibitor LY294002 and not by fulvestrant 
To investigate the mechanism of oestrogen-mediated phosphorylation of Akt, MCF-7 cells 
were treated for 15 min. with oestradiol or Griff C alone or in addition with LY294002, a 
PI3K inhibitor, and Fulvestrant, a pure oestrogen receptor antagonist. 
 
Fig. 33. Regulation of Akt phosphorylation by PI3K inhibitor LY294002: Immunoblot of MCF-7 
treated with vehicle (ethanol) or LY294002 for 15 min. C: control; LY25: 25 mM 
LY294002; LY50: 50 mM LY294002. 
 
While the phosphorylation of Akt was inhibited in cells treated by LY294002 at the 
concentration of 50 µM, no change was observed at 25 µM (Fig. 33). The phosphorylation 
was not affected by fulvestrant alone suggesting that fulvestrant is not directly involved in 
the regulation of Akt phosphorylation. The pre-treatment of MCF-7 cells by either 
fulvestrant or LY294002 did not induce a significant change in the Akt phosphorylation due 
to oestrogen as compared to vehicle treated cells (Fig. 34); the effect of Griff C also was not 
abrogated by LY294002. 
 
Fig. 34. Effect of PI3K inhibitor LY294002 and oestrogen receptor antagonist fulvestrant on the 
phosphorylation of Akt induced by 17β-oestradiol and Griff C. MCF-7 breast cancer cells 
were treated with Griff C (10-6 M), E2 (10-8 M), LY294002 (50mM), fulvestrant (5x10-7 
M), or both Griff C and LY50, or E2 and LY50, or Griff C and Fulvestrant, or E2 and 
fulvestrant for 15 min. 
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5 Discussion  
In the first part of this work, six isoflavones isolated from the plant Millettia griffoniana 
were screened for potential oestrogenic properties. For all of them a positive screening 
result could be obtained by an oestrogenic response in three different in vitro bioassay 
systems. 
5.1 Oestrogenic activity of compounds from Millettia griffoniana in a yeast 
screening assay. 
The first bioassay was based on the recombinant yeast which presents several advantages 
including the lack of known endogenous receptors in wild type yeast, the growth of this 
organism in a media that is devoid of steroids (Zacharewski, 1998), and its weak 
biotransformation activity (Holinka et al., 1986; Le Guevel and Pakdel, 2001). The colour 
change induced by the β-galactosidase suggested that the six O-geranylated isoflavones 
tested were able to directly trigger the β-galactosidase synthesis via the interaction with the 
human oestrogen receptor alpha, since the oestrogenic activity of a substance results from 
its direct interaction with the transferred oestrogen receptor (Zacharewski, 1998). The ER 
previously has shown the ability to bind to an array of compounds with a degree of 
structural diversity (Kuiper et al., 1998). However the potency of each substance may be 
due to its affinity to the oestrogen receptors. Although the yeasts present several 
advantages, many factors can affect the oestrogenic activity of a substance when tested in 
this yeast-based system (Zacharewski, 1998). 
Some limitations of the system might arise from the inability to distinguish anti-oestrogens 
such as fulvestrant from 4-hydroxy-tamoxifen, which exert partial agonist activity in yeast 
(Kohno et al., 1994), as well as differences in permeability for compounds through the yeast 
cell wall (Lyttle et al., 1992; Zysk et al., 1995). For these reasons and for the verification of 
the effects it was necessary to confirm the primary results of the yeast system in additional 
bioassays. 
5.2 Oestrogenic effects of Millettia griffoniana and 17β-oestradiol in MVLN and 
Ishikawa cells  
The substances were further tested in two test systems based on human cells representing 
two target organs, namely the breast cancer cell derived MVLN cells and Ishikawa cells 
from a human endometrial adenocarcinoma. The induction of luciferase in MVLN cells in 
response to the treatment with test compounds confirmed their oestrogenic potency. This 
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corroborates the results of Demirpence et al. (1993) who found this cell line a very effective 
tool to screen natural or synthetic molecules classified as full or partial (anti)oestrogens. In 
this assay, the activity of the reporter gene product was indirectly used to evaluate the 
oestrogen specific transcription activity of a test substance. 
E2 as well as the O-geranylated isoflavones showed moderate oestrogenic potency in 
Ishikawa cells, this could be explained by the fact that Ishikawa cells, like normal uterine 
cells, possess specific metabolic pathways for steroid conversion that modulate the 
sensitivity of the uterus to oestrogens (Falany and Falany, 1996). At a low nanomolar 
oestrogen concentration up to 95% of the oestrogen is converted to the sulphated form 
(Chetrite and Pasqualini, 1997), whereas the oxidation of 17β-oestradiol to estrone by the 
17β-hydroxy-steroid dehydrogenase becomes important at micromolar concentrations (Hata 
et al., 1989). For this reason the concentration of oestradiol as positive control was 10-7 M in 
the Ishikawa based system instead of 10-8 M in the other bioassays used in this work. 
5.3 Antagonism of oestrogenic effects of Millettia griffoniana and 17β-oestradiol 
by fulvestrant in MVLN and Ishikawa cells 
The simultaneous treatment of both human cell lines with isoflavones and the pure 
oestrogen antagonist fulvestrant suppressed oestrogenic effects induced by the test 
substances. This result supports my hypothesis that stimulation of transactivation activity by 
4-O-GIQ, 7-O-GF, Griff E, Griff C, 7-O-GISO, and 7-O-DHF can be mainly attributed to 
oestrogen receptor binding thereby mediating a transcriptional response. Howell et al 
(2000) found that the aptitude of oestrogenic agonists to activate or inhibit the transcription 
in ligand-dependent or independent manner is completely attenuated by fulvestrant. This 
antagonist blocks not only the functional activity of the oestrogenic receptors, but it 
considerably reduces cellular levels of ERs (Howell et al., 2000). 
The screening part of this work was focused on assays which address mainly the ERα 
because the binding affinities of compounds for ERs appear to correlate well with 
phytoestrogen-induced increases in binding of ERα to ERE (Kostelac et al., 2003). 
However it is essential to assess the tested compounds in further assays which address 
oestrogen receptor β (ERβ) subtype only. Many studies suggest that phytoestrogens like 
genistein and daidzein reduce the risk of breast and prostate cancers. The preferential 
binding of isoflavones to ERβ may explain why these compounds reduce the risk of cancers 
in these organs. Previous in vivo studies have demonstrated that ERβ represses some ERα-
mediated effects, including effects on female bone, thymus involution, fat reduction, and 
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proliferative effects in uterus and prostate (Weihua et al., 2000; Weihua et al., 2001). The 
much higher concentrations required for stimulating cell growth than for binding might also 
explain the antiproliferative properties of some phytoestrogens (Morito et al., 2001). 
Unfortunately, an ERβ screening system was not available for this work.  
5.4 Regulation of PCNA, KI-67 and CD1 mRNA expression in MCF-7 cells. 
The mRNA expression of the proliferation associated proteins cyclin D1, PCNA and Ki-67 
was evaluated by real-time PCR in MCF-7 cells. It has been shown that oestradiol at ERα 
and ERβ acts at different steps of the cell cycle: ERα favours entry into cell cycle while 
ERβ transiently inhibits it (Helguero et al., 2005). The lack of a significant effect of Griff C 
on PCNA mRNA expression might be explained by the great affinity of this substance to 
ERβ. PCNA is found during proliferation in most cell phases (Gerdes et al., 1984). Ki-67 is 
expressed in the endometrium in all phases of the cell cycle except in Go (Gerdes et al., 
1984). It is important to underline that the expression of these markers is not always 
accompanied with cellular proliferation; their expression may as well reflect other cellular 
activities like DNA repair (Iatropoulos, 1996). Griff C increased the expression of Ki-67 
mRNA but i did not observe any increase in proliferation of MCF-7 due to the exposure to 
Griff C. The expression of Ki-67 provides information whether cells are in the cell cycle but 
at the same time, there is no informations regarding the length of the cell cycling or wether 
cells are actively cycling. Therefore, the analysis of the expression of PCNA and CD 1 is 
necessary to characterise cells status. 
As far as Cyclin D1 is concerned, its mRNA expression was significantly up regulated in 
MCF-7 cells treated with Griff C and E2. Although cyclin D1 is known to be a key 
regulator of the cell cycle, no association was found between the proliferation index 
(PCNA) and the amplification of cyclin D1. Likewise, no particular increase in cell 
proliferation was observed. This result is consistent with the studies of Buckley (Buckley et 
al., 1993) who found no correlation between CD1 and the proliferation factors PCNA and 
Ki-67. Cyclin D1 expression was found significantly correlated with oestrogen receptor 
positivity in breast cancer (Hui, 1996). Oestrogen likely induces the CD1 mRNA expression 
in MCF-7 ER positive breast cancer cells (Musgrove et al., 1993) through interaction with 
the ER. Other investigators have found that the administration of anti-oestrogen to MCF-7 
rapidly down regulated the CD1 mRNA (Watts et al., 1995). Griff C induced the expression 
of CD1 mRNA probably by the same way as E2.  
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Griff C was one of the most potent isoflavones i tested. The strong in vitro oestrogenic 
effects of Griff C and its chemical structure that predicts a low rate of degradation in vivo, 
prompted us to test this particular substance in ovariectomised wistar rats in vivo. 
5.5. Effects of griffonianone C in ovariectomised rats 
5.5.1. Uterotrophic effects and regulation of oestrogen-regulated genes in the uterus 
Griffonianone C and 17β-oestradiol were administered subcutaneously. The doses were 
selected on the basis of previous knowledge on how in vitro data have to be translated into in 
vivo dosage (Zierau et al., 2004). Unlike treatment with E2, Griff C did not result in an 
increase of the uterine wet weight. Griff C, like daidzein (Diel et al., 2004) was efficient in 
modulating changes in uterine complement C3 gene expression although it lacks the ability to 
stimulate an uterotrophic response in OVX rats. In regard to the weak uterotrophic effect, the 
phytoestrogen genistein induced a statistically significant increase in the uterine wet weight 
only at high doses (Diel et al., 2004). Ovariectomy in rats is usually followed by a reduction 
in cell proliferation and an increase in cell apoptosis. Substituted oestrogens or compounds 
with oestrogen-like activity induce epithelial proliferation and later on an increase in uterine 
weight (Padilla-Banks et al., 2001). The uterotrophic effect of oestrogens has been described 
as biphasic. Water infiltration into epithelial cells is the earlier marker of oestrogen action in 
uterus. This uterine water imbibition, due to enhanced microvascular permeability, increases 
the uterine weight without necessary followed by cells proliferation (Hewitt et al., 2003). 
Increases in uterine weight and epithelial cell proliferation are oestrogenic effects mediated 
by ERα (Cooke et al., 1997, Padilla-Banks et al., 2001; Jefferson et al., 2002). The lack of 
effect of Griff C on the uterine growth might be explained if a higher affinity of this 
compound with ERβ than with ERα is assumed. 
In order to investigate the possible mechanisms by which the compounds regulate mRNA 
expressions, i studied the effect of Griff C on the ERα and ERβ mRNA expression levels. As 
previously reported for E2 in the juvenile rat uterus by Diel et al (2000), and immature mouse 
uterus by Tibbetts et al (1998), i also observed a reduction in the level of both ERs mRNA in 
the uterus of ovariectomised rats after treatment with E2 but also for Griff C. The adult 
uterus, which is a major oestrogen target organ, was found to have in general a very low 
expression of ERβ compared to ERα (Matsuzaki et al., 1999; Kuiper et al., 1997). The failure 
to induce a full uterotrophic response to oestrogen in female ERα knock out mice suggests 
that ERβ plays only a minor role in uterine growth (Weihua et al., 2000). Data on the 
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uterotrophic response to Griff C could be interpreted that this compound might have a 
comparatively high affinity for ERβ; thus the binding of Griff C to ERβ might exert an 
inhibition on uterine growth stimulation by ERα. The decline in uterine ERβ after 72 hours of 
E2 treatment occurred primarily in stromal cells (Weihua et al., 2000). This spatially links 
lower ERβ expression and oestrogen action because oestrogen-induced epithelial cell 
proliferation is mediated by ERs in stromal cells, not primarily by those in the epithelial cells 
themselves (Cooke et al., 1997). This decline in ER mRNAs could result from decreased 
transcription or increased degradation of both receptors. A possible implication of these 
results is that a reduction in ERβ levels might be necessary for oestrogen and other ER 
activators to exert their full trophic effects on the uterus (Weihua et al., 2000). This latter 
findind was further supported by Diel et al (2004) who reported that the ratio of ERα relative 
to ERβ increases following E2 treatment of OVX rats while genistein does not mimic this 
response.  
0-geranylated isoflavones isolated from Millettia griffoniana exhibited at high doses 
oestrogenic effects in a reporter gene system with MVLN cells expressing ERα and in 
Ishikawa cells. I hypothesized that these compounds bind ERα with low affinity and therefore 
a large amount of substance is needed for oestrogenic responses. Obviously, these compounds 
can induce, at least partially, the conformational changes involved in the formation of a 
transcriptionally competent activation function in the ligand-binding domain (Brzozowski et 
al., 1997). Thus beside the classical uterotrophic assay the gene expression analysis can 
provide more detailed information on the molecular function of oestrogen-like chemicals and 
their mode of action (Newbold et al., 2001; An et al., 2002). 
It was previously demonstrated that the down-regulation of Clusterin as well as the up 
regulation of complement C3 gene expressions are sensitive markers for oestrogenic action 
in the uterus (Diel et al., 2000; Wunsche et al., 1998; Vollmer and Schneider, 1996). As 
expected, the expression of the complement C3 mRNA was strongly increased in response 
to E2 and Griff C while a significant reduction of the expression of clusterin (CLU) was 
found. I also observed a dose-dependent down-regulation of clusterin mRNA expression 
induced as response to Griff C. The repression of the clusterin mRNA expression has been 
described in various steroid-hormone-sensitive tissues like the uterus and the prostate 
(Guenette et al., 1994a), (Guenette et al., 1994b). While C3 is stimulated in both intact 
uterine tissue and tumor tissues, clusterin is repressed in intact uterine tissue (Diel et al., 
2001) and up-regulated in tumours (Wunsche et al., 1998). These findings, confirmed by 
results with C3 and CLU, characterize the tissue-specific expression of some genes. 
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Interestingly a binding site for the transcription factor AP-1 was identified on the CLU 
promotor (Gutacker et al., 1999). This site is the probable sensitive and regulatory element 
for the transcriptional effect of Griff C. Matthews et al (2006) have reported that ERβ may 
preferentially antagonize the nonclassical AP-1-mediated pathway regulated by 
ERα.(Matthews et al., 2006). ERβ altered the recruitment patterns of both c-Fos and c-Jun 
to oestrogen-responsive promoter sites of genes. 
The COX 2 mRNA expression was strongly decreased in the uterus of OVX rats by both E2 
and Griff C. These findings supported the results of Diel et al. (1996) who found a strong 
transient induction of COX 2 in the uterus of OVX rats and a down-regulation in the vena 
cava of the same experimental animals. 
Oestrogenic effects on expression of uterine CaBP-9kD gene are due to direct 
transcriptional regulation. The promotor of the CaBP-9kD gene comprises an imperfect 
palindromic oestrogen-response element which mediates oestrogen receptor binding and 
oestrogen-dependent activity (Darwish et al., 1991). The positive effect of Griff C at the 
dose 20 mg/kg BW although distinctly lower than that of E2, suggested that Griff C exerts 
its action through the mediation of the ERE at the promoter region of the CaBP-9kD gene. 
It has been shown that the expression of angiogenic factors such as VEGF is regulated by 
oestrogens and partial oestrogen agonists in both hormone responsive cancers and normal 
target tissue (Hyder et al., 1999; Hyder et al., 2000). VEGF mRNA expression increases in 
the uterus following E2 treatment as previously observed in rodents (Cullinan-Bove and 
Koos, 1993; Hyder et al., 1996; Shweiki et al., 1993), human tissue (Charnock-Jones, 1993; 
Shifren et al., 1996), and cell lines (Charnock-Jones et al., 1993). I found a down-regulation 
of VEGF in the uterus of ovariectomised rats by E2 and Griff C. 
Although there are some findings suggesting an oestrogenic regulation of VEGF-expression 
due at least in part to a direct transcriptional action of oestrogen receptors, there have been 
no reports of the presence of a functional ERE in the VEGF gene (Hyder et al., 2000). 
However, an ERE analogous of the consensus element is located in the 3’-URT of the 
VEGF gene and functions as a classical enhancer for oestrogen receptors (Curtis and 
Korach, 1991). 
VEGF transcripts are elevated in human tumours, including those responsive to steroid 
hormones (Hyder, 2000); so consequently, substances that decrease or suppress VEGF may 
contribute to inhibit tumour growth (Kim et al., 1992). Mitogenic and angiogenic effects of 
VEGF are enhanced by the presence of its specific receptor VEGF-2. Little is known about 
the mechanisms of regulation of VEGF receptors in the human endometrium. In the 
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endometrium of rats, the expression VEGFR-2 is regulated by oestrogen and progesterone. 
This expression is associated with the expression of neurophilin 1 (Pavelock et al., 2001) 
Progesterone receptor expression plays a key role in the mediation of progesterone–induced 
actions and is modulated in uterus by E2 (Hughes et al., 2004). I could observe that PR 
mRNA expression was down-regulated by both E2 as well as Griff C at all doses tested. 
These results corroborate the findings of Bebington et al. (2000) and Zierau et al. (2004), who 
described a decrease of PR mRNA expression in the uterus of ovariectomised rats after 
administration of E2. Given the fact that in ovariectomised rats not only the production of 
endogenous E2 is disrupted but also the synthesis of progesterone, the reduction of the PR 
mRNA level is not due to the over-stimulation of PR receptors. The capacity of oestrogens to 
repress the epithelial PR expression is an event more closely related to ERβ than to ERα. In 
fact ERβ knock out mice have lost the capacity to down-regulate PR after E2 administration 
in the luminal epithelium (Weihua et al., 2003). Studies to examine mechanisms underlying 
the regulation of PR expression in rat have revealed that the PR gene contains in its promoter 
region, four weak, but functional, imperfect oestrogen response elements (EREs), each 
differing from the consensus by 2 base pairs. (Kraus et al., 1994) 
IGF-1 mediates at least partially oestrogen-induced proliferation in uterus (Murphy et al., 
1987; Norstedt et al., 1989). In this work, both 17β-oestradiol and Griff C decreased the 
IGF-1 mRNA levels in the uterus of ovariectomised rats. This finding is contradictory to 
other investigators who found increased IGF-1 mRNA levels in the rodent uterus after 
oestrogen treatment (Murphy et al., 1987; Norstedt et al., 1989; Sato et al., 2002). 
Additionally the treatment of ovariectomised rats with IGF-1 results in an increase of 
uterine weight compared to controls (Sato et al., 2002). I found a correlation between the 
down-regulation of IGF-1 in the uterus and the trophic effect of Griff C. In studies with 
IGF-1 knock out mice, it was shown that not only the locally produced IGF-1 uterine 
development and epithelial proliferation affects, but also the systemic levels of IGF-1 play 
an important role (Roy et al., 2000). In contrast to tamoxifen which increases the IGF-1 
mRNA expression in uterus, and therefore the risk of endometrial carcinoma in women, the 
oestrogenic properties of Griff C coupled with its lack of effect on the IGF-1 mRNA 
expression might be useful as a potential alternative for women with an endometrial cancer 
risk.  
The strong correlation observed in E2 treated rats between effects on uterotrophy and C3, 
CLU, and CaBP-9kD mRNA expression was not seen for Griff C. Griff C did not induce an 
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uterotrophic response but it affected the expression of oestrogen-sensitive genes in the 
uterus.  
In the uterus, C3 and CaBP 9kD genes that contain ERE in their promoter region were 
upregulated by Griff C. CLU and IGF-1 which are regulated through the transcription factor 
AP-1 were down-regulated by Griff C. Genes like PR and VEGF with incomplete ERE in 
their promoter domains were also down-regulated by Griff C. There is suggestive evidence 
that AP-1 alternate pathways play an important role in oestrogen-dependent proliferation 
(Paech et al., 1997; Shang and Brown, 2002). The antagonistic effect of Griff C at the AP-1 
alternate element might explain its non uterotrophic action. 
Oestrogens are capable of influencing several physiological functions in tissues with non-
reproductive tasks like the liver, blood vessels and many others. 
 
5.5.2. Oestrogen-mediated gene expression in liver  
The expression of some hepatic proteins is regulated indirectly by oestrogens via the 
modulation of pituitary growth hormone secretion (v.Schoultz and Carlström, 1989). 
Several other hepatic genes were shown to underlie direct regulation through the hepatic 
oestrogen receptor ({Ohkubo et al., 1986). I have observed an up-regulation of IGFBP-1 
mRNA induced by E2 in the liver of OVX rats while it was down-regulated by Griff C. 
IGFBP-1 is synthesised in the liver and is highly expressed in the decidualised rat uterus 
({Bell et al., 1988}). Its production in liver was first shown to be regulated by growth 
hormone, insulin, dexamethasone, phorbol esters, catecholamines and glucagon (Kachra et 
al., 1994; Luo et al., 1990; Hooper et al., 1994; Thissen et al., 1994). The regulation of 
IGFBP-1 by E2 in liver and uterus has also been demonstrated this last decade (Molnar and 
Murphy, 1994; Diel et al., 1995). The discrepancy observed in my work between the effects 
of E2 and of Griff C on the IGFBP-1 mRNA expression might be explained by the 
distribution of ERs in the liver, which expresses only ERα. These data support my 
hypothesis that the affinity of Griff C might be higher for ERβ than for ERα. 
The E2 regulation of acute phase protein genes has been reported in the literature 
(Krattenmacher et al., 1994). The Major acute phase (MAP) protein is closely related, but not 
identical, to T-kininogen (Cole et al., 1985; Furuto-Kato et al., 1985) which is a component of 
the kininogen-kallikrein-kinin system that mediates events occurring during the inflammatory 
response, (Heinrich et al., 1990; Fung and Schreiber, 1987). Although Griff C increased the 
MAP mRNA expression in the liver, it decreased the COX 2 mRNA expression in uterus and 
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liver, suggesting that Griff C by decreasing the COX 2 mRNA expression prevent the 
production of prostaglandins, which play a key role in the inflammatory process. Another 
compound, Griffonianone D, isolated from Millettia griffoniana has been shown by Yankep 
et al. (2003) to possess anti-inflammatory properties. 
In this study, ovariectomy of rats did not enhance carbonic anhydrase gene expression as 
Zheng et al (1995) reported. Griff C (20 mg/kg BW) and E2 (10 µg/kg BW) did not 
increase the expression of CA 2 in OVX rats. These findings are interesting because in 
previous studies Zheng et al. (1995) suggested that oestrogen prevents bone loss by 
reducing the mRNA levels of osteoclastic bone-resorbing enzymes (Tartrate-resistant acid 
phosphatase and carbonic anhydrase 2) in bone tissue. Griff C has a biphasic effect on the 
expression of CA 2 in liver; at lower doses Griff C increased the CA 2 mRNA expression. 
CA 2 is transcriptionally upregulated by c-Fos/AP-1. A functional AP-1 binding site is 
present in the CA 2 promoter and is necessary for its regulation (David et al., 2001) 
Hepatic ApoA-I mRNA and hepatic nuclear factors 3 gamma (HNF-3γ) mRNA levels 
decreased after the treatment with Griff C and E2. The gene encoding ApoA-I, the 
predominant protein in the anti-atherosclerotic high-density lipoprotein, contains a powerful 
liver specific enhancer (Lamon-Fava et al., 1999; Jin et al., 1998). In vivo, Griff C and E2 
reduced ApoA-I, while Lamon-fava et al (Lamon-fava and Mivherone, 2004) have shown 
that E2 and Genistein increase apoA-I gene expression in liver cells. This increase was 
shown to be mediated by the enhancer of apoA-I promoter. The binding of HNF-3γ to its 
corresponding sites stimulates ApoA-I enhancer activity synergistically via conjoint 
recruitment of transcriptional coactivators (Widom et al., 1991; Harnish et al., 1996). The 
strong reduction of the HFN-3γ mRNA expression by both Griff C and E2 observed in this 
work might have led to the reduction of the HFN-3γ production, as result reducing the 
HFN-3γ induction of ApoA-I. Targeted disruption of the HNF-3γ gene has been shown to 
decrease expression of several liver-specific genes (Kaestner et al., 1998). 
5.5.3. Oestrogen-induced gene expression in vena cava 
As previously observed in the uterus, the ERα mRNA expression was repressed by E2, while 
Griff C showed no significant effect, which is consistent with the data of Knauthe et al 
(1996). Both Griff C and E2 increased the expression of PR mRNA in the vena cava. PRs are 
expressed in vascular cells (Lee et al., 1997b; Knauthe et al., 1996; Ingegno et al., 1988) and 
PR expression in vascular tissues is induced by oestrogen (Knauthe et al., 1996), supporting 
that direct vascular effects of progestins and/or oestrogen may be mediated in part by PRs. 
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The mechanism by which Griff C trigged the expression of PR is likely to be related to the 
functional ERE in the promoter of the PR gene (Kastner et al., 1990; Kraus et al., 1994). 
The VEGF and VEGFR-2 mRNA expression in the vena cava was not affected either by E2 
or Griff C except Griff C at the dose 10 mg/kg BW which slightly increased the mRNA 
expression of both genes. A high expression of VEGFR-2 is observed in capillaries during 
the proliferative and early-mid secretory periods (Meduri et al., 2000), suggesting that in 
vena cava, Griff C like E2 could modulate VEGF activity,  through VEGFR-2 expression or 
directly. Regulation of angiogenesis and vascular permeability are essential for the 
physiological functioning of the reproductive tract. 
The ACE mRNA expression was investigated in the vena cava to evaluate potential 
cardiovascular protective action of Griff C further. This effect was compared to that of 
oestradiol, which displays a cardioprotective effect mediated in large part by modulating the 
metabolism of lipoproteins. E2 has been shown to increase HDL cholesterol and decrease 
plasma LDL cholesterol; it also attenuates oxidized LDL production. These actions 
contribute to reduction of risk for coronary arteriosclerosis (Gallagher et al., 1999). ACE is 
a key enzyme of the renin-angiotensin system that plays a central role in the regulation of 
blood pressure and cardiac function. An up-regulation of ACE results in the degradation of 
bradykinin, which acts as potent vasodilatator of peripheral arteries. Bradykinin exerts its 
action through a variety of mechanisms, including the release of nitric oxide, prostaglandins 
and endothelial-derived hyperpolarizing factors (Gallagher et al., 1999). Some investigators 
observed a reduction of plasma ACE after longterm treatment of ovariectomised animals 
(Seltzer et al., 1992). The mechanism of action of E2 at the ACE regulation level is still 
unclear. No ERE is reported in the 5’ flanking region of the ACE coding sequence. 
However, the ACE promoter contains a consensus AP-1 site and it is believed that the ACE 
mRNA regulation by oestrogen treatment is mediated by the interaction of oestrogen 
receptors with the Fos-Jun heterodimer at an AP-1 site (Gallagher et al., 1999). 
The critical role of nitric oxide has been revealed for VEGF-induced angiogenesis, as well 
as for vascular permeability (Parenti et al. 1998; Morbidelli et al., 1996). The formation of 
nitric oxide itself can be regulated via the insulin-like growth factor I (IGF-I) system 
(Wickman et al., 2002). Nitric oxide formed by the endothelial nitric oxide synthase 
(eNOS) has been shown to play an important role in the physiological regulation of local 
blood flow and blood pressure. Oestrogens can up-regulate the eNOS 3 isoform mRNA 
expression (Forstermann et al., 1998). eNOS 3 expression is increased in pregnant and 
oestrogen-treated rats (Goetz, 1994); medullary NOS 3 levels are also increased in animals 
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after oestrogen replacement therapy (Neugarten et al., 1997). In contrast to these data, 
oestradiol or Griff C showed no effects on the eNOS 3 expression in the vena cava in my 
study. These findings may be explained by the fact that the distribution of eNOS is different 
in the two vessel types, veins and arteries (Wickman et al., 2002) and moreover the eNOS 
expression in aorta is mainly mediated by IGF-1 whereas in vein another indirect 
mechanism of growth hormone is involved. Additionally 17β-oestradiol was shown to 
inhibit excessive nitric oxide production by inducible nitric oxide synthase (iNOS) in rat 
aorta by decreasing iNOS mRNA and protein expression (Kauser et al., 1998). 
In the vena cava contrary to the oestrogen-induction of PCNA reported in tumour tissue, there 
is no interference of Griff C and E2 in the induction of PCNA. As marker for cell 
proliferation, the absence or reduction of PCNA implies a cytostatic effect. It is important to 
note that in ovariectomised rats treated with E2, PCNA mRNA expression level increases 
some few hours after treatment, but after 3 days exposure to E2, this increase drops to basal 
level (Diel et al., 2004). 
Unlike in uterine and liver tissues where Griff C and E2 strongly decreased the CLU mRNA 
expression, in the vena cava of the same set of animals, this expression was significantly 
increased by E2, whereas Griff C had almost no effect. As observed in the uterus, COX 2 
mRNA expression was down-regulated by Griff C and E2. The inflammatory mechanisms 
seem not to be affected by Griff C in vena cava like in the uterus and the liver of 
ovariectomised rats. 
5.6. In vitro regulation of Akt activation in MCF-7 breast cancer cells 
Oestradiol and several oestrogenic compounds (genistein for example) are though to exert 
their biological activities by at least two principal mechanisms: one termed genomic and the 
other non-genomic (Beyer, 1999). Besides its effects in stimulating proliferation, oestradiol 
also acts as survival factor by activating antiapoptotic molecules such as Akt. Genomic 
effects of oestradiol that involve an interaction of ERs with ERE in the promoter region of a 
target gene or protein-protein interactions on chromatin (Enmark and Gustafsson, 1999) 
take hours to produce maximal responses. In contrast, the non-genomic effects of 
oestrogens induce maximum responses only within few minutes after treatment (Guzeloglu 
Kayisli et al., 2004; Wade et al., 2001). 
Oestrogens in target cells expressing ERα and/or ERβ stimulate rapid signalling pathways. 
However, these signalling pathways can be activated in cells without endogenous ER. It has 
been shown that oestradiol is able to regulate a signalling pathway involving related 
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tyrosine and MAP kinases (Gruber et al., 2002). Akt is an oncogenic protein abnormally 
expressed in many oestrogen receptor positive or negative cancer cells. It can promote cell 
multiplication by reducing apoptosis. (Blume-Jensen and Hunter, 2001; Gong et al., 2003). 
The activation of Akt leads to regulation of downstream targets molecules, resulting in 
antiapoptotic effects. Phosphorylated Akt activates NFκB protein (Kane et al., 1999), 
promoting the expression of anti-apoptotic genes (Wang et al., 1996). Akt also 
phosphorylates caspase 9, inhibiting the protease activity directly (Cardone et al., 1998). 
Phosphorylation of the pro-apoptotic Bad protein by Akt also decreases apoptosis by 
preventing Bad from binding and inhibiting an anti-apoptotic protein called Bcl-xL (Datta 
et al., 1997) 
The critical role of activated Akt in antiapoptotic processes suggests that Akt is an excellent 
target for cancer prevention and treatment. Griff C by slightly increasing the expression of 
the activated form of Akt might in addition to its biological activity through the genomic 
pathway also upon the non genomic pathway. However i did not investigate the expression 
or activarion of the downstream effectors of Akt. 
In contrast to genistein which was shown to down-regulate the expression of total Akt 1 and 
phosphorylated Akt at Ser473 in ER negative MDA-MB-231 cells (Gong et al., 2003), the 
isoflavone Griff C slightly increased the phosphorylated Akt levels in ER positive MCF-7 
cells. Klotz et al. (2002) have found that oestradiol does not induce phosphorylation of Akt 
in endometrial cells of ERα knockout mice, suggesting that this activation is ERα 
dependent. Generally, the balance of ER isoforms may contribute to oestrogen-mediated 
effects on Akt signalling.  
LY294002 has blocked the phosphorylation of Akt confirming its effects as inhibitor of 
PI3K, the upstream activator of Akt. In contrast, fulvestrant did not antagonize the E2-
induced Akt activation, suggesting that ER binding to DNA is not required for this effect 
(Guzeloglu Kayisli et al., 2004).  
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6 Conclusion and future outlook 
All O-geranylated isoflavones derived from Millettia griffoniana were assayed for the first 
time to detect their oestrogenic activity. These compounds were able to exert an oestrogenic 
activity in vitro, detected by induction of the β-galactosidase, the luciferase and the alkaline 
phosphatase activity. In addition, for Griff C oestrogenic properties could be verified in vivo. 
The expression of various relevant oestrogen-responsive genes was regulated by 
Griffonianone C and the spectrum of its gene regulation activity was clearly similar to that of 
17β-oestradiol. However, the action of Griff C remained relatively weak in comparison to the 
effects of E2. This finding is consistent with the potencies of many other phyto- and xeno-
oestrogens that have been shown to be 100-1000 times less potent compared to E2 (Zava and 
Duwe, 1997; Miksicek, 1994; Santell et al., 1997; Gutendorf and Westendorf, 2001). The 
spectrum of activity of the here investigated substances was partly different from the effects 
of oestradiol probably because of their dissimilar affinities to ERα and ERβ. Unlike genistein, 
the isoflavones tested in this work in in vitro reporter gene assays did not support the concept 
of biphasic dose response model characterised by the ability of a compound to induce 
stimulation at a low dose and inhibition at higher doses (Calabrese and Baldwin, 2003). For 
the effect of Griff C on genes expression, the biphasic response pattern was observed for IGF-
1, CLU and COX2 (in uterus); VEGF, VEGF-R2 and Ki-67 (in vena cava). This ability of 
Griff C to induce biphasic response depending on the doses is interesting. 
Based on results from the current study, the use of this plant in the traditional medicine to 
alleviate menopausal symptoms and to handle menstrual disorders might present a simple and 
low cost medication. However, the risk of promoting endometrial and breast cancer in 
menopausal women should be considered because most oestrogenic compounds do also 
induce cell proliferation and, thereby, increasing the risk of stimulating carcinogenesis. Griff 
C is advantagous because it did not increase the uterine weight. In addition, in all test systems 
used in this work, Griff C does not show any proliferative effect. The observed oestrogenic 
effects of Griff C and the fact that it has no proliferative actions makes Griff C to be a good 
candidate molecule that could be used safely in patients with breast or endometrium cancer 
risk.  
To discuss the common use of Millettia griffoniana in the treatment of boils, insect bites and 
asthma, establishment of additional test systems addressing additional functional endpoints is 
required.  
For the future, it would also be interesting to assess the expression of genes regulated by 
Grifff C at the protein level. This would strengthen the results obtained so far. In this initial 
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in vivo study, Griff C was applied by subcutaneous injection to ovariectomised rats. The 
aim of the pharmacological approach was to prove in vivo effectiveness of Griff C; this is 
why i used the sub cutaneuous protocol. Since Griff C is administered orally to humans in 
the traditional medicine as concoctions, it will be necessary to design an experiment, which 
will attempt to mimic human exposure to Griffonianone C. Therefore, a per os protocol of 
treatment will be performed. In the new experimental design, it will be possible for example 
to complete the pharmacological assessment of Griff C and to test its bioavailability after 
passage of Griff C through the gastrointestinal tract, where it may be subjected to 
transformations. To attempt to potentiate the effects of Griff C and other isoflavones tested 
in this work, it will be necessary to chemically modify their structures by substitution. De 
novo synthesized substances will then be tested in the different in vitro bioassays i have 
already used in this work.  
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Appendix 
The sources and manufactures of chemicals, reagents and devices used in this work are 
summarised below. 
A. Chemicals  
A.1 Reagent for human cell culture 
 
Product Manufacturer 
10x Insulin-Transferrin-Selenium-A-
Supplement 
Invitrogen Life Technology (Karlsruhe, 
Germany) 
Active charcoal Serva (Heidelberg, Germany) 
Alkaline phosphatase (17U/mg) Sigma (Taufkirchen, Germany) 
Bovine serum albumin Serva (Heidelberg, Germany) 
Carbon dioxide Linde (Dresden, Germany) 
Dextran Sigma (Taufkirchen, Germany) 
Dimethylsulfoxid (DMSO) Roth (Karslruhe,Germany) 
Di-sodium phosphate (Na2HPO4) VWR (Darmstadt, Germany) 
DMEM/F12 without phenol red GIBCO-BRL (Berlin, Germany) 
Foetal calf serum(FCS) Biochrom AG(Berlin, Germany 
Gentamycin Biochrom AG (Berlin, Germany) 
Glutamine Biochrom AG (Berlin, Germany) 
Liquid nitrogen Linde (Dresden, Germany) 
Mannitol Sigma (Taufkirchen, Germany) 
Penicilline/Streptomycin Biochrom AG (Berlin, Germany) 
P-nitrophenylphosphate (PNPP) Roche (Mannheim, Germany) 
Potassium Chloride (KCl) J.T. Baker (Greilsheim, Germany) 
Potassium hydrogenphosphat (KH2PO4) VWR (Darmstadt, Germany) 
Sodium chloride (NaCl) J.T. Baker (Greilsheim, Germany) 
Sodium hydroxide (NaOH) VWR (Darmstadt, Germany) 
Sodium pyruvate (100 mM) Biochrom AG (Berlin, Germany) 
Trypsin-EDTA  Biochrom (Berlin, Germany) 
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A.2 Reagents for yeast culture 
Product Manufacturer 
Adenin  Sigma (Taufkirchen, Germany) 
Biotine Sigma (Taufkirchen, Germany) 
Chlorophenol red β-D-galactopyranoside 
(CPRG) 
Roche (Mannheim, Germany) 
Copper (II) sulphate Sigma (Taufkirchen, Germany) 
D-(+)-Glucose Sigma (Taufkirchen, Germany) 
D-Pantothen acid Sigma (Taufkirchen, Germany) 
Inositol Sigma (Taufkirchen, Germany) 
L-Arginin-HCl Sigma (Taufkirchen, Germany) 
L-Asparagin acid Sigma (Taufkirchen, Germany) 
L-Glutamic acid Sigma (Taufkirchen, Germany) 
L-Histidin Sigma (Taufkirchen, Germany) 
L-Isoleucin Sigma (Taufkirchen, Germany) 
L-Leucin Sigma (Taufkirchen, Germany) 
L-Lysin-HCl Sigma (Taufkirchen, Germany) 
L-Methionin Sigma (Taufkirchen, Germany) 
L-Phenylalanin Sigma (Taufkirchen, Germany) 
L-Serin Sigma (Taufkirchen, Germany) 
L-Threonin Sigma (Taufkirchen, Germany) 
L-Tyrosin Sigma (Taufkirchen, Germany) 
L-Valin Sigma (Taufkirchen, Germany) 
Magnesium sulphate Sigma (Taufkirchen, Germany) 
Potassium hydrogenphosphat (KH2PO4) VWR (Darmstadt, Germany) 
Potassium hydroxide (KOH) Sigma (Taufkirchen, Germany) 
Pyridoxine Sigma (Taufkirchen, Germany) 
Thiamine Sigma (Taufkirchen, Germany) 
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A.3 Reagents for RNA extraction  
Product Manufacturer 
Chloroform Roth (Karlsruhe, Germany) 
Diethylpyrocarbonate (DEPC) Serva (Heidelberg, Germany) 
Ethanol VWR (Darmstadt, Germany) 
J.T. Baker (Greilsheim, Germany) 
PeqGOLD Trifast™ PegLab Biotechnology(Erlangen, Germany) 
RNaseZap® Sigma (Taufkirchen, Germany) 
TRIzol™  Invitrogen Life Technology (Karlsruhe, 
Germany) 
 
A.4 Reagents for Desoxyribonuclease digestion and cDNA synthesis 
Product Manufacturer 
AVM reverse transkriptase Promega (Heidelberg, Germany) 
Desoxyribonuclease I (DNase I) Roche (Mannheim, Germany) 
dNTPs (dATP, dCTP, dGTP, dTTP) Invitrogen Life Technologies (Karlsruhe, 
Germany) 
DTT Invitrogen Life Technologies (Karlsruhe, 
Germany) 
EDTA Promega (Mannheim, Germany) 
Oligo(dT)12-18-Nucleotide MWG (Ebersberg, Germany) 
RNA inhibitor (RNase out) Invitrogen Life Technologies (Karlsruhe, 
Germany) 
SuperScript® II reverse transcriptase Invitrogen Life Technologies (Karlsruhe, 
Germany) 
5x First strand buffer Invitrogen Life Technologies (Karlsruhe, 
Germany) 
10x PCR buffer Invitrogen Life Technologies (Karlsruhe, 
Germany) 
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A.5 PCR-Reagents 
Product Manufacturer 
10x PCR buffer Invitrogen Life Technologies (Karlsruhe, 
Germany) 
dNTPs (dATP, dCTP, dGTP, dTTP) Invitrogen Life Technologies (Karlsruhe, 
Germany) 
Fluorescein calibration dye Bio-Rad (München, Germany) 
HPLC J.T. Baker (Greilsheim, Germany) 
Magnesiumchloride (MgCl2) Invitrogen (Carlsbad, USA) 
Oligonucleotide primers (see table ) MWG (Ebersberg, Germany) 
Eurogentec GmbH (Köln, Germany). 
Platinum® Taq DNA polymerase Invitrogen Life Technologies (Karlsruhe, 
Germany) 
SybrGreen I Sigma-Aldrich (Taufkirchen, Germany) 
 
A.6 Oligonucleotide primers 
Primers sequences used in this study are summarised below. Primers for rats, 1A, ERα, 
ERβ, PR, C3, PCNA, COX 2, CLU, Ki-67, ACE, CA 2, MAP, CaBP 9kD, IGFBP-1, Apo 
A1, HNF-3γ, NOS 3, VEGF, VEGF-R2, and IGF-1 were purchased from the company 
MWG (Ebersberg, Germany). Human Ki-67 and human CD1 were obtained from 
Eurogentec GmbH (Köln, Germany).  
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A.7 Reagents fof agarose gel electrophoresis 
Product  manufacturer 
Acetic acid VWR (Darmstadt, Germany) 
Agarose  Invitrogen Life Technologies (Karlsruhe 
Germany) 
Bromophenol blue ICN (Eschwege, Germany) 
DNA Ladder (100bp) Invitrogen Life Technologies (Karlsruhe 
Germany) 
Ethidium bromide Sigma (Taufkirchen, Germany) 
Ethylen dinitrotetraoxide acid (EDTA) Sigma (Taufkirchen, Germany) 
Sucrose Serva (Heidelberg, Germany) 
Tris Roth (Karlsruhe, Germany) 
Xylencyanol ICN (Eschwege, Germany) 
 
A.8 Reagents for PAGE and Western blot 
Product Manufacturer 
2-Mercaptoethanol Sigma (Taufkirchen, Germany) 
Acetic acid Merck (Darmstadt, Germany) 
Acrylamid solution 30% ProtoGel® ; National diagnostic (Atlanta, USA) 
Rotiphorese®, 37.5:1 Roth 
Ammoniumperoxidisulfat  Roth (Karlsruhe, Germany) 
Ammoniumsulfat Sigma (Taufkirchen, Germany) 
Biotin solution Sigma (Taufkirchen, Germany) 
Bovine serum albumin Serva (Heidelberg, Germany) 
CAPS Sigma (Taufkirchen, Germany) 
Carbonate Merck (Darmstadt, Germany) 
Coomassie brilliant blue G-250 Roth (Karlsruhe, Germany) 
Developer (Centrabroms) Tetenal (Norderstedt, Germany) 
DTT (Dithiothreitol) GIBCO-BRL (Berlin, Germany) 
Fixator (Superfix plus) Tetenal (Norderstedt, Germany) 
Glycerine VWR (Darmstadt, Germany) 
Glycine Serva (Heidelberg, Germany) 
Roth (Karlsruhe, Germany) 
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Hydrogenchloride (HCl) Sigma (Taufkirchen, Germany) 
Methanol Sigma (Taufkirchen, Germany) 
N,N,N’,N’-Tetramethylethylen-diamin 
(TEMED) 
Roth (Karlsruhe, Germany) 
peqGOLD Protein marker IV 
(prestained)range (10-160 kDa) 
PegLab Biotechnology( Erlangen, Germany) 
Ponceau S Sigma (Taufkirchen, Germany) 
Protease inhibitor  Roche (Mannheim, Germany) 
Skim milk Becton Dickinson (San jose, USA) 
Sodiumchlorite J. T. Baker (Greilsheim, Germany) 
Sodiumdodecylsulfate (SDS)  Roth (Karlsruhe, Germany) 
Sodiumhydroxid Merck (Darmstadt, Germany) 
Tris-(hydoxymethyl)-aminomethane Roth (Karlsruhe, Germany) 
Tween® 20 Roth (Karlsruhe, Germany) 
 
B. Supplies 
Product Manufacturer 
“Glasperlen” Roth (Karlsruhe, Germany) 
96 thin-wall PCR plate Bio-Rad (München, Germany) 
96-well microtiter plates Roth (Karlsruhe, Germany) 
Cell culture flasks (25 cm2, 75cm2) TPP (Trasadingen, Switzerland) 
Cell culture plates (6-, 12-, and 24-
wells)  
TPP (Trasadingen, Switzerland) 
Cryo tubes (2 ml) VWR (Darmstadt, Germany) 
Film (PCR) Bio-Rad (München, Germany) 
Filter (0.22 µm pore size), Sterivac-
GP10 
Millipore (Eschborn, Germany) 
Filter, (0.2 µm pore size ),Mediakap-2 Bioscience ( Fernwald, Germany) 
Haemocytometer, Neubauer VWR (Darmstadt, Germany) 
Nitrocellulose membrane (0.0025 µm 
pore diameter) 
Millipore VS (Eschborn, Germany) 
Parafilm foil, Parafilm M American National Can™ 
Pipette tips Biozym (Hessisch Oldendorf, Germany) 
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PVDF membrane, Immobilon™-P 
(0.45 µm pore size) 
Millipore VS (Eschborn, Germany) 
Reaction tube (0.2 ml) Biozym (Hessisch Oldendorf, Germany) 
Reaction tubes (1.5 ml, 2 ml) Greiner Bio-one, (Frickenhausen, Germany) 
Reaction tubes (15 ml, 50 ml) Greiner Bio-one, (Frickenhausen, Germany) 
Sterile filter Schleicher and Scuell (dassel, Germany) 
Tungsten-carbide ball  B. Braun Biotech International, (Melsungen, 
Germany) 
X-ray films, Hyperfilm™ Amersham Pharmacia Biotech (Freiburg, 
Germany) 
 
C. Equipments  
Device Model Company 
Agarose gel electrophoresis 
system 
Mini systems Mini-
PROTEAN® 3 cell 
Polymer systems Bio-Rad 
Autoclave Steam Sterilizer SANOclar,  
Bain-marie 1002-1013 GFL, Burgwedel 
Balance BP211D Satorius, Göttingen 
Blockthermostat (heating 
block) 
Granz Boekel Neolab®, Heidelberg 
Centrifuge Biofuge pico Heraeus, Hanau 
Centrifuge Biofuge fresco Heraeus, Hanau 
Centrifuge Megafuge 2.0 R Heraeus, Hanau 
Centrifuge Avanti™ J-25 Heraeus, Hanau 
Centrifuge Multifuge 3 S-R Heraeus, Hanau 
Dismembrator Micro-Dismembrator S B. Braun, Biotech International, 
Melsungen 
Exposure cassette  Hypercassette™ Amersham Pharmacia Biotech, 
Freiburg 
Gel electrophoresis system Mini-Protean® 3 Cell Bio-Rad, München 
Heating block Granz Boekel Neolab®, Heidelberg 
Incubator HERA Cell Heraeus, Hanau 
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Inverted microscope CK40 Olympus, Hamburg 
IQ real-time PCR detection 
system 
Icycler Bio-Rad, München 
Laminar flow hood HERA Safe Heraeus, Hanau 
Liquid nitrogen tank  Air liquid, Düsseldorf 
Microwave R-232 Sharp 
Minishaker Test Tube Shaker Merck® Eurolab 
Multi-channel pipetter  Eppendorf, Hamburg 
Multiplate reader Genios Tecan, Crailsheim,  
pH-meter MP 220 Mettler Toledo 
Photometer Specord 200 Analytik Jena, Jena 
Pipette aid  Eppendorf, Hamburg 
Power supply  Power Pac 300 Bio-Rad, München 
Refrigerator  Liebherr 
Scanner Storm Amersham Pharmacia Biotech, 
Freiburg 
Semi-dry blotter Trans-Blot® SD Bio-Rad, München 
Shaking incubator Thermoshake Gerhardt, Bonn 
Teflon “container”   B. Braun, Biotech International, 
Melsungen 
Thermocycler (PCR) Primus 96 plus MWG Biotech, Ebersberg 
Thermocycler (PCR) Primus MWG Biotech, Ebersberg 
Ultra-sound desintregrator  Brandelin electronic, Berlin 
UV light box  MWG-Biotech, Ebersberg 
Vacuum pump  Vacuum Brand, 
Werthheim 
Vacuum concentrator DNA Speed vac® 110 Savant Instruments, 
Farmingdale, USA 
Vortex  Eurolab, Bonn 
Water distiller  Elga (Ransbach-Baumbach) 
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D. Kits used 
Product Manufacturer 
BCA-1 Assay (kit for protein 
determination) 
Sigma (Taufkirchen, Germany) 
ECL plus Amersham Biosciences (Freiburg, Germany 
ECL™ Amersham Biosciences (Freiburg, Germany) 
Luciferase assay kit (Promega 1501) Promega (Heidelberg, Germany) 
 
E. Antibodies 
Primary antibodies  
Rabbit anti-Akt, polyclonal Cell Signaling technology (Beverly, USA) 
Rabbit anti-Phosphorylated-Akt  
(Ser 473), polyclonal 
Cell Signaling technology (Beverly, USA) 
 
Secondary antibody  
Goat anti-rabbit IgG horseradish 
peroxidase conjugated  
Jackson Immuno Research (Soham, UK)  
 
F. Software used 
 
Optical density measurement WinAspect software package version 1.3 
from Analytik Jena (Jena, Germany) 
 
Colorimetric detection,  
quantification of total protein,  
and detection of luminescence 
Magellan software package (Tecan, 
Crailsheim, Germany) 
 
PCR analysis iCycler IQ optical system software version 
3.0 a (Bio-rad, München, Germany) 
 
Statistical analysis XLSTAT-Pro (version 7.1, Addinsoft) 
 
Graph plotting SigmaPlot® 9.0 (Systat Software 
GmbH, Erkrath, Germany) 
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